Myriad Genetics (MYGN) 10-K 13 Aug 20 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2020	Aug. 07, 2020	Dec. 31, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Trading Symbol	MYGN
Entity File Number	0-26642
Entity Tax Identification Number	87-0494517
Entity Address, Address Line One	320 Wakara Way
Entity Address, City or Town	Salt Lake City
Entity Address, Postal Zip Code	84108
City Area Code	801
Local Phone Number	584-3600
Entity Address, State or Province	UT
Entity Registrant Name	MYRIAD GENETICS, INC.
Entity Central Index Key	0000899923
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Public Common Stock, $0.01 par value
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Annual Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		74,709,313
Entity Public Float			$ 2,029,635,485
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement, to be filed no later than 120 days following June 30, 2020, for the Annual Meeting of Stockholders to be held on December 4, 2020.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Current assets:
Cash and cash equivalents	$ 163.7	$ 93.2
Marketable investment securities	54.1	43.7
Prepaid expenses	13.8	16.6
Inventory	29.1	31.4
Trade accounts receivable	68.1	133.9
Prepaid taxes		25.1
Other receivables	2.9	4.7
Total current assets	331.7	348.6
Property, plant and equipment, net	37	57.3
Operating lease right-of-use assets	66
Long-term marketable investment securities	37	54.9
Intangibles, net	605.3	684.7
Goodwill	327.6	417.2
Total assets	1,404.6	1,562.7
Current liabilities:
Accounts payable	21.7	33.3
Accrued liabilities	75.9	78.9
Current maturities of operating lease liabilities	13.5
Short-term contingent consideration	3.1	3.4
Deferred revenue	32.8	2.2
Total current liabilities	147	117.8
Unrecognized tax benefits	23.5	21.7
Noncurrent operating lease liabilities	56.9
Other long-term liabilities	4.3	7.8
Contingent consideration	3.7	10.4
Long-term debt	224.4	233.5
Long-term deferred taxes	26.6	82.6
Total liabilities	486.4	473.8
Commitments and contingencies
Stockholders’ equity:
Common stock, 74.7 and 73.5 shares outstanding at June 30, 2020 and 2019 respectively	0.7	0.7
Additional paid-in capital	1,096.6	1,068
Accumulated other comprehensive loss	(5.2)	(5.4)
Retained earnings (accumulated deficit)	(173.9)	25.6
Total Myriad Genetics, Inc. stockholders' equity	918.2	1,088.9
Total stockholders' equity	918.2	1,088.9
Total liabilities and stockholders’ equity	$ 1,404.6	$ 1,562.7

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares shares in Millions	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement Of Financial Position [Abstract]
Common stock, shares outstanding	74.7	73.5	70.6	68.4

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Millions	3 Months Ended									12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Total revenue	$ 93.2	$ 164	$ 195.1		$ 186.3	$ 215.4	$ 216.6	$ 216.8	$ 202.3	$ 638.6	$ 851.1	$ 743.7
Costs and expenses:
Research and development expense	17.4	19.7	18.8		21.3	20.9	21.5	22.4	21.1	77.2	85.9	70.8
Change in the fair value of contingent consideration		(3.4)	(0.1)		0.7	(0.3)		1	0.4	(2.8)	1.1	(61.2)
Selling, general, and administrative expense	107.4	132.9	134.3		135.5	149.8	140.6	135.2	129.9	510.1	555.5	435
Goodwill and intangible asset impairment charges		98.4	1.3							99.7
Total costs and expenses	161.5	297.7	203.9		207.2	221	210.7	210.7	201.1	870.3	843.5	621.8
Operating income (loss)	(68.3)	(133.7)	(8.8)		(20.9)	(5.6)	5.9	6.1	1.2	(231.7)	7.6	121.9
Other income (expense):
Interest income	0.5	0.8	0.8		0.9	0.9	0.7	0.9	0.7	3	3.2	1.8
Interest expense	(3.1)	(2.3)	(2.5)		(2.9)	(3.2)	(3.2)	(3.4)	(2.2)	(10.8)	(12)	(3.2)
Other	12.4	4.1	(0.9)		0.6	0.2	(0.1)		1.1	16.2	1.2	(0.4)
Total other income (expense):	9.8	2.6	(2.6)		(1.4)	(2.1)	(2.6)	(2.5)	(0.4)	8.4	(7.6)	(1.8)
Income (loss) before income tax	(58.5)	(131.1)	(11.4)		(22.3)	(7.7)	3.3	3.6	0.8	(223.3)		120.1
Income tax benefit	(3)	(15.9)	(3.1)		(1.7)	(3.4)	(3.6)	1	1.6	(23.7)	(4.4)	(13)
Net income (loss)	(55.5)	(115.2)	(8.3)		(20.6)	(4.3)	6.9	2.6	(0.8)	(199.6)	4.4	133.1
Net loss attributable to non-controlling interest	(0.1)					(0.1)			(0.1)	(0.1)	(0.2)	(0.2)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (55.4)	$ (115.2)	$ (8.3)		$ (20.6)	$ (4.2)	$ 6.9	$ 2.6	$ (0.7)	$ (199.5)	$ 4.6	$ 133.3
Earnings (loss) per share:
Basic	$ (0.74)	$ (1.55)	$ (0.11)		$ (0.28)	$ (0.06)	$ 0.09	$ 0.04	$ (0.01)	$ (2.69)	$ 0.06	$ 1.92
Diluted	$ (0.74)	$ (1.55)	$ (0.11)		$ (0.28)	$ (0.06)	$ 0.09	$ 0.03	$ (0.01)	$ (2.69)	$ 0.06	$ 1.85
Weighted average shares outstanding:
Basic	74.6	74.5	74.4		73.7	73.4	73.3	74.2	73	74,300,000	73,500,000	69,400,000
Diluted	74.6	74.5	74.4		73.7	74.8	74.9	76.5	73	74,300,000	76,000,000	72,000,000
Molecular Diagnostic Testing [Member]
Total revenue	$ 83.3	$ 150.5	$ 181.1		$ 172	$ 196.9	$ 200.5	$ 203	$ 189	$ 586.9	$ 789.4	$ 690.4
Costs and expenses:
Total costs and expenses	32.2	43.1	41		41.2	41.6	40.3	44	42.3	157.5	168.2	148.7
Pharmaceutical and Clinical Services [Member]
Total revenue	9.9	13.5	14		14.3	18.5	16.1	13.8	13.3	51.7	61.7	53.3
Costs and expenses:
Total costs and expenses	$ 4.5	$ 7	$ 8.6		$ 8.5	$ 9	$ 8.3	$ 8.1	$ 7.4	$ 28.6	$ 32.8	$ 28.5
[1]	An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (199.5)	$ 4.6	$ 133.3
Unrealized gain (loss) on available-for-sale securities, net of tax	0.7	1.2	(0.4)
Change in pension liability		0.6	0.3
Change in foreign currency translation adjustment	(0.6)	(3.1)	1.6
Comprehensive income (loss)	$ (199.4)	$ 3.3	$ 134.8

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common Stock [Member]	Additional paid-in capital [Member]	Accumulated other comprehensive loss [Member]	Retained earnings (accumulated deficit) [Member]
Beginning Balance at Jun. 30, 2017	$ 767.4	$ 0.7	$ 851.4	$ (5.5)	$ (79.2)
Issuance of common stock under share-based compensation plans	36.9		36.9
Share-based payment expense	27.1		27.1
Net income (loss)	133.3				133.3
Other comprehensive income (loss), net of tax	1.4			1.4
Ending Balance at Jun. 30, 2018	966.1	0.7	915.4	(4.1)	54.1
Issuance of common stock under share-based compensation plans	136		136
Share-based payment expense	33.5		33.5
Repurchase and retirement of common stock	(50)		(16.9)		(33.1)
Net income (loss)	4.6				4.6
Other comprehensive income (loss), net of tax	(1.3)			(1.3)
Ending Balance at Jun. 30, 2019	1,088.9	0.7	1,068	(5.4)	25.6
Issuance of common stock under share-based compensation plans	3.4		3.4
Share-based payment expense	25.2		25.2
Net income (loss)	(199.5)				(199.5)
Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary	0.1			0.1
Other comprehensive income (loss), net of tax	0.1			0.1
Ending Balance at Jun. 30, 2020	$ 918.2	$ 0.7	$ 1,096.6	$ (5.2)	$ (173.9)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (199.5)	$ 4.6	$ 133.3
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	72	73	54.4
Non-cash interest expense	0.5	0.4	0.2
Gain on deconsolidation of subsidiary	(1)
Gain on disposition of assets		(0.9)	(0.2)
Share-based compensation expense	25.2	33.5	27.1
Deferred income taxes	(55.8)	18.6	(23.5)
Unrecognized tax benefits	1.7	(5.5)	(0.3)
Impairment of goodwill and intangible assets	99.7
Change in fair value of contingent consideration	2.8	(1.4)	(60.9)
Payment of contingent consideration		(1.5)	(22.7)
Changes in assets and liabilities:
Prepaid expenses	2.2	(3.2)	3.3
Trade accounts receivable	64	(18.2)	(9.1)
Other receivables	0.6	(0.7)	1.1
Inventory	1.6	8	7.9
Prepaid taxes	25.1	(25.1)
Accounts payable	(10.7)	1.1	4
Accrued liabilities	1.6	1.5	1.4
Deferred revenue	30.7	(0.5)	(0.1)
Net cash provided by operating activities	60.7	83.7	115.9
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures	(10.2)	(8.6)	(8.4)
Acquisitions, net of cash acquired		(278.5)
Proceeds from sale of subsidiary	21.3
Purchases of marketable investment securities	(60.8)	(78.5)	(80.9)
Proceeds from maturities and sales of marketable investment securities	69	79.2	77.7
Net cash provided by (used in) investing activities	19.3	(286.4)	(11.6)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from common stock issued under share-based compensation plans	3.5	8.7	36.9
Proceeds from revolving credit facility		340	53
Repayment of revolving credit facility	(8.6)	(115)	(143)
Payment of contingent consideration recognized at acquisition	(3.9)		(42.4)
Fees associated with refinancing of revolving credit facility	(1)	(1.4)
Repurchase and retirement of common stock		(50)
Proceeds from non-controlling interest			0.5
Net cash provided by (used in) financing activities	(10)	182.3	(95)
Effect of foreign exchange rates on cash and cash equivalents	0.5	2.7	(0.8)
Net increase (decrease) in cash and cash equivalents	70.5	(17.7)	8.5
Cash and cash equivalents at beginning of year	93.2	110.9	102.4
Cash and cash equivalents at end of year	$ 163.7	$ 93.2	$ 110.9

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Financial Statement Presentation Myriad Genetics, Inc. and subsidiaries (collectively, the Company) is a leading personalized precision medicine company acting as a trusted advisor to transform patient lives through pioneering molecular diagnostics. The Company employs a number of proprietary technologies, including DNA, RNA and protein analysis, that help it to understand the genetic basis of human disease and the role that genes and their related proteins may play in the onset and progression of disease. The Company uses this information to guide the development of new molecular diagnostic and companion diagnostic tests that are designed to assess an individual’s risk for developing disease later in life (predictive medicine), identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment (personalized medicine), or assess a patient’s risk of disease progression and disease recurrence (prognostic medicine). The Company generates revenue by performing molecular diagnostic tests as well as by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters are located in Salt Lake City, Utah. The accompanying consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company” or “Myriad”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with U.S. GAAP. Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of fixed assets, valuation allowances for receivables and deferred income tax assets, certain accrued liabilities, share-based compensation, valuation of intangible assets from acquisitions and impairment analysis of goodwill and intangible assets. Actual results could differ from those estimates. The full impact of the COVID-19 outbreak continues to evolve and its future impacts remain highly uncertain and unpredictable. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for future periods. Concentration of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s account receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 15%, 14% and 17% of total revenue for the fiscal years ended June 30, 2020, 2019 and 2018, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. No Marketable Investment Securities The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company’s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash. A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against “Other income” when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company’s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the fiscal years ended June 30, 2020, 2019 and 2018. Inventory Inventories consist of reagents, plates and testing kits. Inventories are stated at the lower of cost or market on a first-in, first-out basis. In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company evaluates its inventories for excess quantities and obsolescence. Inventories that are considered obsolete are expensed. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management’s assessment of current and expected orders from the Company’s customers. Trade Accounts Receivable Trade accounts receivable represents amounts billed to customers for revenue recognized related to molecular diagnostic tests and pharmaceutical and clinical services. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral. Property, Plant and Equipment Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from three to seven years. Repairs and maintenance costs are charged to expense as incurred. Intangible Assets and Other Long-Lived Assets Intangible and other long-lived assets are comprised of acquired licenses, technology and intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets. The classification of the Company’s acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. Goodwill Goodwill is tested for impairment by reporting unit on an annual basis as of April 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill is first assessed using a qualitative approach. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed. The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results. Revenue Recognition In May 2014, The Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted this standard as of July 1, 2018, utilizing the full retrospective method of adoption allowed by the standard, in order to provide for comparative results in all periods presented. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally customers make payments prior to the Company's performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During 2020, the Company received approximately $29.7 in advance Medicare payments as part of the CARES Act, which was enacted on March 27, 2020 to provide relief from the economic impacts of COVID-19. The advance Medicare payments are included in prepayments of deferred revenue. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below: Years Ended June 30, 2020 2019 Deferred revenue - beginning balance $ 2.2 $ 2.6 Revenue recognized (7.2 ) (7.9 ) Prepayments 37.8 7.5 Deferred revenue - ending balance $ 32.8 $ 2.2 Myriad generates revenue by performing molecular diagnostic testing and pharmaceutical and clinical services. Revenue from the sale of molecular diagnostic tests and pharmaceutical and clinical services is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of clinical and pharmaceutical services indicates transfer of control for revenue recognition purposes. In accordance with ASU 2014-09, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, periodically the Company enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical and clinical services that may have terms longer than one year and include multiple performance obligations. As of June 30, 2020, the aggregate amount of the transaction price of such contracts that is allocated to the remaining performance obligations is $2.7. The Company provides financial assistance programs to its patients and volume discounts to payors. In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collection from third-party payors. An estimate of transaction price does not include any estimated amount of variable consideration that are constrained. The Company applies the expected value method for sales where the Company has a large number of contracts with similar characteristics. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value under the new standard, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. In accordance with Accounting Standards Update No. 2016-02, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for e.g. sales tax, value added tax etc. During the three and twelve months ended June 30, 2020, the Company recognized a $0.4 decrease and $9.9 decrease in revenue, respectively, which resulted in no impact to earnings (loss) per share for the three months ended June 30, 2020 and a $(0.10) impact to earnings (loss) per share for the twelve months ended June 30, 2020, for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. During the fourth quarter of fiscal year 2020, the Company identified an error related to prior periods for Medicare claims and has reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error in the current period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the current period resulted in an impact to earnings (loss) per share for the three and twelve months ended June 30, 2020 of $ (0.05) The Company has elected to apply the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company has also elected to apply the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and vast majority of payments terms have a payback period of less than one year. The following table represents the Company’s revenue by type for the years ended June 30, 2020, 2019, and 2018: Years Ended June 30, (In millions) 2020 2019 2018 Molecular diagnostic revenues: Hereditary Cancer Testing $ 347.4 $ 479.7 $ 471.4 GeneSight 74.1 112.6 124.9 Prenatal 76.7 104.9 — Vectra 39.1 48.3 55.2 Prolaris 24.7 25.5 21.5 EndoPredict 10.5 10.4 8.8 Other 14.4 8.0 8.6 Total molecular diagnostic revenue 586.9 789.4 690.4 Pharmaceutical and clinical service revenue 51.7 61.7 53.3 Total revenue $ 638.6 $ 851.1 $ 743.7 Share-based payment expense We recognize the fair value compensation cost relating to share-based payment transactions in accordance with Accounting Standards Codification (“ASC”) 718, Compensation – Stock Compensation. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee’s requisite service period, which is generally the vesting period. The fair value of restricted stock units is based on the number of shares granted and the quoted price of the Company’s common stock on the grant date. Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of our stock price. Other Income The Company recognizes stimulus or grant payments that it receives that do not need to be paid back as other income. During the year ended June 30, 2020, the Company received approximately $14.6 from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that are attributable to COVID-19, which is recognized as a component of other income in the consolidated statements of operations. Income Taxes The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company’s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows. Earnings Per Share Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Years Ended June 30, 2020 2019 2018 Denominator: Weighted-average shares outstanding used to compute basic EPS 74.3 73.5 69.4 Effect of dilutive stock options — 2.5 2.6 Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 74.3 76.0 72.0 Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Years Ended June 30, 2020 2019 2018 Anti-dilutive options and RSUs excluded from EPS computation 5.5 0.8 — Foreign Currency The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in accumulated other comprehensive loss as a separate component of stockholders’ equity. The following table shows the cumulative translation adjustments included in accumulated other comprehensive loss: Ending balance June 30, 2019 $ (7.2 ) Period translation adjustments (0.6 ) Reclassification upon deconsolidation of subsidiary 1.3 Ending balance June 30, 2020 $ (6.5 ) Transaction gains and losses are included in the determination of net income (loss) in the consolidated statements of operations. Recent Accounting Pronouncements Standards Effective in Future Years and Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”) which introduces new guidance for the accounting for credit losses on certain instruments within its scope. ASU 2016-13 introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. For trade receivables, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses, which reflects losses that are probable. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. ASU 2016-13 is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. Early application of the guidance is permitted for all entities for fiscal years beginning after December 15, 2018, including the interim periods within those fiscal years. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. The Company will adopt ASU 2016-13 on July 1, 2020 and does not expect the adoption to have a material impact on its consolidated financial statements or financial statement disclosures. In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software, including hosting arrangements that include an internal-use software license. This guidance is effective for public entities for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years, with early adoption permitted. The Company will adopt ASU 2018-15 on July 1, 2020 on a prospective basis and expects the adoption will result in amounts related to implementation costs that were previously expensed to be capitalized on the balance sheet. Recently Adopted Standards In February 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and changing certain lessor accounting requirements. ASU 2016-02 also requires entities to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. On July 1, 2019, the Company adopted ASU 2016-02 under the modified retrospective approach by initially applying ASU 2016-02 at the adoption date, rather than at the beginning of the earliest comparative period presented. Results for the fiscal year ended June 30, 2020 are presented under ASU 2016-02. Prior period amounts were not adjusted and continue to be reported under previous lease accounting guidance. Under ASU 2016-02, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company’s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term. ASU 2016-02 provides a number of optional practical expedients in transitioning to ASU 2016-02. The Company has elected the package of practical expedients to avoid reassessing under ASU 2016-02 prior conclusions about lease identification, lease classification and initial direct costs. The Company has also elected the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use ROU assets based on all facts and circumstances through the effective date of the new standard. ASU 2016-02 also provides practical expedients for ongoing lease accounting. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize ROU assets or lease liabilities for those leases that qualify as a short-term lease (leases with lease terms of 12 months or less), which includes not recognizing ROU assets or lease liabilities for existing short-term leases in transition. The Company also has elected the practical expedient to avoid separating lease and non-lease components for any of its leases within its existing classes of assets. As of the July 1, 2019 adoption date, the Company recognized operating lease liabilities of $78.8 and right-of-use assets related to operating leases totaling $74.5 as of the adoption date. These are presented as “Current maturities of operating lease liabilities” for a total of $13.1, “Noncurrent operating lease liabilities” for a total of $65.7, and “Operating lease right-of-use assets” for a total of $74.5 on the Company’s consolidated balance sheet. No adjustments to the beginning retained earnings balance were required. On October 1, 2019, the Company early adopted ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) (“ASU 2017-04”) as permitted under the standard. The standard simplifies the accounting for goodwill impairment by requiring a goodwill impairment to be measured using a single step impairment model, whereby the impairment equals the difference between the carrying amount and the fair value of the specified reporting units as a whole. This eliminates the second step of the current impairment model that requires a company to first estimate the fair value of all assets in a reporting unit and measure impairments based on those fair values and a residual measurement approach. The standard also specifies that any loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This ASU was adopted on a prospective basis with no material impact to the Company’s consolidated financial statements.

Marketable Investment Securitie

Marketable Investment Securities	12 Months Ended
	Jun. 30, 2020
Investments Debt And Equity Securities [Abstract]
Marketable Investment Securities	2 . MARKETABLE INVESTMENT SECURITIES The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at June 30, 2020 and 2019 were as follows: Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At June 30, 2020: Cash and cash equivalents: Cash $ 132.8 $ — $ — $ 132.8 Cash equivalents 30.9 — — 30.9 Total cash and cash equivalents 163.7 — — 163.7 Available-for-sale: Corporate bonds and notes 50.1 0.8 — 50.9 Municipal bonds 17.8 0.2 — 18.0 Federal agency issues 5.5 0.1 — 5.6 US government securities 16.4 0.2 — 16.6 Total $ 253.5 $ 1.3 $ — $ 254.8 Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At June 30, 2019: Cash and cash equivalents: Cash $ 68.7 $ — $ — $ 68.7 Cash equivalents 24.5 — — 24.5 Total cash and cash equivalents 93.2 — — 93.2 Available-for-sale: Corporate bonds and notes 64.0 0.6 — 64.6 Municipal bonds 15.3 — — 15.3 Federal agency issues 9.0 — — 9.0 US government securities 9.7 — — 9.7 Total $ 191.2 $ 0.6 $ — $ 191.8 Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at June 30, 2020: Amortized Estimated cost fair value Cash 132.8 132.8 Cash equivalents 30.9 30.9 Available-for-sale: Due within one year 53.7 54.1 Due after one year through five years 36.1 37.0 Due after five years — — Total $ 253.5 $ 254.8 There were no debt securities classified as available-for-sale in a gross unrealized loss position as of June 30, 2020 or 2019. Additional information relating to fair value of marketable investment securities can be found in Note 3.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. FAIR VALUE MEASUREMENTS The fair value of the Company’s financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value of contingent consideration related to the Sividon acquisition as well as the long-term debt were categorized as a Level 3 liability, as the measurement amount is based primarily on significant inputs not observable in the market. The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2— observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the earn out period utilizing various potential pay-out scenarios. Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn out itself, the related projections, and the overall business. The contingent consideration liabilities are classified as a component of long-term and short-term contingent consideration in the Company’s consolidated balance sheets. Changes to the contingent consideration liabilities are reflected in change in the fair value of contingent consideration in our consolidated statements of operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements. The fair value of our long-term debt, which we consider a Level 3 measurement, is estimated using discounted cash flow analyses, based on the Company’s current estimated incremental borrowing rates for similar borrowing arrangements. The fair value of long-term debt is estimated to be $225.5 at June 30, 2020 and $192.7 at June 30, 2019. During the quarter ended December 31, 2019, there was a triggering event that required the Company to perform an impairment analysis for the Clinic reporting unit. As a result, the Company recognized a $1.3 impairment charge for goodwill. The fair value used to determine the impairment charge, which we consider a Level 3 measurement, was based on the expected sale price of the Clinic from a recent purchase offer. During the quarter ended March 31, 2020, there was a triggering event that required the Company to perform an impairment analysis for the Crescendo Bioscience reporting unit. As a result, the Company recognized a $80.7 impairment charge for goodwill. We consider the fair value used to determine the impairment charge to be a Level 3 measurement. See additional discussion relating to the Company’s goodwill impairment in Note 5. The following tables set forth the fair value of the Company’s financial assets and liabilities that are re-measured on a regular basis: Level 1 Level 2 Level 3 Total June 30, 2020 Money market funds (a) $ 30.9 $ — $ — $ 30.9 Corporate bonds and notes — 50.9 — 50.9 Municipal bonds — 18.0 — 18.0 Federal agency issues — 5.6 — 5.6 US government securities — 16.6 — 16.6 Contingent consideration — — (6.8 ) (6.8 ) Total $ 30.9 $ 91.1 $ (6.8 ) $ 115.2 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. Level 1 Level 2 Level 3 Total June 30, 2019 Money market funds (a) $ 17.2 $ — $ — $ 17.2 Corporate bonds and notes 2.5 64.4 — 66.9 Municipal bonds — 15.4 — 15.4 Federal agency issues — 9.0 — 9.0 US government securities — 9.8 — 9.8 Contingent consideration — — (13.8 ) (13.8 ) Total $ 19.7 $ 98.6 $ (13.8 ) $ 104.5 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. The following table reconciles the change in the fair value of the contingent consideration during the periods presented: Carrying Amount Balance June 30, 2019 $ 13.8 Payment of contingent consideration (3.9 ) Change in fair value recognized in the statement of operations (2.8 ) Translation adjustments recognized in other comprehensive income (0.3 ) Balance June 30, 2020 $ 6.8

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Property, Plant and Equipment, Net	4 . PROPERTY, PLANT AND EQUIPMENT, NET Years Ended June 30, 2020 2019 Land $ — $ 2.3 Buildings and improvements — 18.8 Leasehold improvements 31.8 31.0 Equipment 112.1 117.1 143.9 169.2 Less accumulated depreciation (106.9 ) (111.9 ) Property, plant and equipment, net $ 37.0 $ 57.3 During the third quarter of fiscal year 2020, the Company sold the Clinic resulting in the deconsolidation of $19.5 of the balance of property, plant and equipment. See Note 16 for additional information regarding the sale of the Clinic. Years Ended June 30, 2020 2019 2018 Depreciation expense $ 11.0 $ 13.7 $ 17.1

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Jun. 30, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	5 . GOODWILL AND INTANGIBLE ASSETS Goodwill The changes in the carrying amount of goodwill for the years ended June 30, 2020 and 2019 are as follows: Diagnostic Other Total Years Ended June 30, Years Ended June 30, Years Ended June 30, 2020 2019 2020 2019 2020 2019 Beginning balance $ 351.6 $ 252.8 $ 65.6 $ 65.8 $ 417.2 $ 318.6 Acquisitions (see note 19) — 94.9 — — — 94.9 Adjustments to acquisitions (see note 19) — 4.4 — — — 4.4 Goodwill deconsolidated on sale of Clinic — — (7.3 ) — (7.3 ) — Goodwill impairment charge (80.7 ) — (1.3 ) — (82.0 ) — Translation adjustments (0.2 ) (0.5 ) (0.1 ) (0.2 ) (0.3 ) (0.7 ) Ending balance $ 270.7 $ 351.6 $ 56.9 $ 65.6 $ 327.6 $ 417.2 As a result of the effect of COVID-19 on expected future cash flows and a corresponding decline in market capitalization and enterprise value, the Company performed an interim quantitative impairment review of goodwill for the Assurex, Crescendo Bioscience and Myriad International reporting units as of March 31, 2020. The Company estimated the fair values of each reporting unit using both the market approach, applying a multiple of earnings based on observable multiples for guideline publicly traded companies, and the income approach, discounting future cash flows based on management’s expectations of the current and future operating environment for each reporting unit. The Company corroborated the reasonableness of the estimated reporting unit fair values by reconciling to its enterprise value and market capitalization. Based on this analysis, the Company recognized a goodwill impairment charge of $ 80.7 related to the goodwill from the Crescendo reporting unit in the third quarter of fiscal year 2020. The Crescendo reporting unit is part of the Company’s diagnostic segment. The calculation of the impairment charge includes substantial fact-based determinations and estimates including weighted average cost of capital, future revenue, profitability, cash flows and fair values of assets and liabilities. The goodwill impairment charge is reflected in goodwill and intangible asset impairment charges in the Consolidated Statements of Operations. As a result of further decline in market capitalization and enterprise value during the fourth quarter, the Company also performed an interim quantitative impairment review of goodwill for the Assurex, Crescendo Bioscience and Myriad International reporting units as of June 30, 2020. The Company estimated the fair values of each reporting unit using both the market approach, applying a multiple of earnings based on observable multiples for guideline publicly traded companies, and the income approach, discounting future cash flows based on management’s expectations of the current and future operating environment for each reporting unit. The Company corroborated the reasonableness of the estimated reporting unit fair values by reconciling to its enterprise value and market capitalization. The goodwill balance at each reporting unit was determined not to be impaired as of June 30, 2020. The Company recognized a $1.3 impairment charge for goodwill allocated to the Clinic asset group during the second quarter of fiscal year 2020 that is included in goodwill and intangible asset impairment charges in the Consolidated Statements of Operations. The Clinic asset group was part of the Company’s other segment. See Note 16 for further discussions regarding the deconsolidation of goodwill upon the closing of the sale of the Clinic. The Company did not record an impairment of goodwill for the periods ended June 30, 2019 or 2018. Intangible Assets Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, developed technology, a laboratory database, trademarks, and customer relationships as well as non-amortizable intangible assets of in-process technologies, research and development. The Company’s developed technology and database acquired have estimated remaining useful lives between 3 and 16 years, trademarks acquired have an estimated remaining useful life of approximately 8 years and customer relationships have an estimated remaining useful life of approximately 1 year. The estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets. The classification of the acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. During the third quarter of fiscal year 2020, the Company decided to abandon the development of one of its in-process research and development intangible assets, and as a result the Company recognized a charge of $17.7, which is reflected in goodwill and intangible asset impairment charges in the Consolidated Statements of Operations. The in-process research and development intangible asset was reported as part of the Company’s diagnostic segment. The Company concluded there was no impairment of long-lived assets for the years ended June 30, 2020, 2019 and 2018. The following summarizes the amounts reported as intangible assets: Gross Carrying Accumulated At June 30, 2020: Amount Amortization Net Purchased licenses and technologies $ 815.6 $ (217.1 ) $ 598.5 Customer relationships 4.6 (4.2 ) 0.4 Trademarks 3.0 (1.4 ) 1.6 Total amortizable intangible assets 823.2 (222.7 ) 600.5 In-process research and development 4.8 — 4.8 Total unamortized intangible assets 4.8 — 4.8 Total intangible assets $ 828.0 $ (222.7 ) $ 605.3 Gross Carrying Accumulated At June 30, 2019: Amount Amortization Net Purchased licenses and technologies $ 815.7 $ (156.6 ) $ 659.1 Customer relationships 4.6 (3.8 ) 0.8 Trademarks 3.0 (1.2 ) 1.8 Total amortizable intangible assets 823.3 (161.6 ) 661.7 In-process research and development 23.0 — 23.0 Total unamortized intangible assets 23.0 — 23.0 Total intangible assets $ 846.3 $ (161.6 ) $ 684.7 As of June 30, 2020 the weighted average remaining amortization period for purchased licenses and technologies, trademarks, and customer relationships is approximately 11 years The Company recorded amortization during the respective periods for these intangible assets as follows: Years Ended June 30, 2020 2019 2018 Amortization of intangible assets $ 61.0 $ 59.3 $ 37.3 Amortization expense of intangible assets is estimated to be $51.9 in 2021, $45.0 in 2022, $43.6 in 2023, $43.4 in 2024 and $43.4 in 2025 and $373.2 thereafter.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Jun. 30, 2020
Payables And Accruals [Abstract]
Accrued Liabilities	6 . ACCRUED LIABILITIES Years Ended June 30, 2020 2019 Employee compensation and benefits $ 47.4 $ 48.8 Accrued taxes payable 6.1 3.0 Qui tam settlement — 9.1 Other 22.4 18.0 Total accrued liabilities $ 75.9 $ 78.9

Long-Term Debt

Long-Term Debt	12 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Long-Term Debt	7 . LONG-TERM DEBT On December 23, 2016, the Company entered into a senior secured revolving credit facility (the “Facility”) as borrower, with the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 to the Facility (the “Amended Facility”), which effected an “amend and extend” transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 to $350.0. On May 1, 2020, the Company entered into Amendment No. 2 to the Amended Facility, which waived the Company’s compliance with certain covenants and modified the interest rate and other terms during the Amendment Period from March 31, 2020 through June 30, 2021 (“Amendment Period”). Both amendments were accounted for as modifications pursuant to guidance in ASC 470-50. Pursuant to the Amended Facility, the Company borrowed revolving loans in an aggregate principal amount of $300.0 with $1.8 in upfront fees and $0.3 debt issuance costs recorded as a debt discount to be amortized over the term of the Amended Facility. The Company incurred an additional $1.0 in upfront fees as a result of Amendment No. 2, which was also recorded as a debt discount that will be amortized over the term of the Amended Facility. The current balance of the net long-term debt is $224.4. There are no scheduled principal payments of the Amended Facility prior to its maturity date . The proceeds of the Amended Facility were used to: (i) refinance in full the obligations under the Facility, (ii) finance the acquisition of Counsyl (See Note 19), (iii) pay fees, commissions, transactions costs and expenses incurred in connection with the foregoing, and (iv) for working capital and other general corporate purposes. The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Amended Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balances and the undrawn fee was increased to 50 basis points during the Amendment Period, at which point they return to the existing pricing of 200 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points based on the Company’s leverage ratio. The LIBOR floor was also increased to 1.0% during the Amendment Period. The interest rate as of June 30, 2020 was 4.5%. Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company’s ability to incur additional indebtedness, create certain types of liens or complete mergers or consolidations, and/or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company’s ability to sell assets, pay dividends or provide other distributions to shareholders. The Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility’s compliance with the leverage ratio covenant and the interest coverage ratio covenant, which were waived through March 31, 2021. A minimum liquidity covenant was added for the period beginning May 2020 until March 2021, and a minimum EBITDA covenant was added for the second and third quarter of fiscal year 2021. Amendment No. 2 also revises certain negative covenants of the Amended Facility during the Amendment Period. The Company was in compliance with all financial covenants at June 30, 2020. During the years ended June 30, 2020, 2019 and 2018 the Company made $8.6, $115.0 and $143.0 in principal repayments, respectively. The Amended Facility is secured by a first-lien security interest in substantially all of the assets of Myriad and certain of its domestic subsidiaries and each such domestic subsidiary of Myriad has guaranteed the repayment of the Amended Facility . Amounts outstanding under the Amended Facility were as follows: Years Ended June 30, 2020 2019 Long-term debt $ 226.7 $ 235.0 Long-term debt discount (2.3 ) (1.5 ) Net long-term debt $ 224.4 $ 233.5

Other Long Term Liabilities

Other Long Term Liabilities	12 Months Ended
	Jun. 30, 2020
Other Liabilities Disclosure [Abstract]
Other Long Term Liabilities	8 . OTHER LONG-TERM LIABILITIES Years Ended June 30, 2020 2019 Pension obligation $ — $ 6.8 Other 4.3 1.0 Total other long-term liabilities $ 4.3 $ 7.8 The Company’s balance of other long-term liabilities for the year ended June 30, 2020 consists of Company’s portion of social security taxes that have been deferred under the CARES Act that do not have to be deposited until December 2021 and December 2022. The Company previously held two non-contributory defined benefit pension plans for its current and former Clinic employees. The Company has closed participation in the plans to exclude those employees hired after 2002. As of June 30, 2019 the fair value of the plan assets were approximately $0.1 resulting in a net pension liability of $6.8. The Company sold the Clinic in February 2020 and as a result the net pension liability was removed upon deconsolidation. See Note 16 for further discussion regarding the sale of the Clinic.

Preferred and Common Stockholde

Preferred and Common Stockholder's Equity	12 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Preferred and Common Stockholder's Equity	9 . PREFERRED AND COMMON STOCKHOLDER’S EQUITY The Company is authorized to issue up to 5.0 shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at June 30, 2020, 2019 and 2018. The Company is authorized to issue up to 150.0 shares of common stock, par value $0.01 per share. There were 74.7, 73.5, and 70.6 shares issued and outstanding at June 30, 2020, 2019 and 2018 respectively. Common shares issued and outstanding Years Ended June 30, 2020 2019 2018 Common stock issued and outstanding at July 1 73.5 70.6 68.4 Common stock issued upon exercise of options and employee stock plans 1.2 4.5 2.2 Repurchase and retirement of common stock — (1.6 ) — Common stock issued and outstanding at June 30 74.7 73.5 70.6 Stock Repurchase Program In June 2016, the Company’s Board of Directors authorized a share repurchase program of $200.0 of the Company’s outstanding common stock. The Company plans to repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company’s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of June 30, 2020, the Company has $110.7 remaining on its current share repurchase authorization. During the year ended June 30, 2019 the Company used $50.0 to repurchase shares of the Company’s stock as part of an accelerated share repurchase. The Company uses the par value method of accounting for its stock repurchases. As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to retained earnings/accumulated deficit. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to retained earnings/accumulated deficit for the repurchases for periods ended June 30, 2020, 2019 and 2018 were as follows: Year ended June 30, 2020 2019 2018 Shares purchased and retired — 1.6 — Common stock and additional paid-in-capital reductions $ — $ 16.9 $ — Charges to retained earnings $ — $ 33.1 $ —

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation	10. SHARE-BASED COMPENSATION On November 30, 2017, the Company’s shareholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants and directors. The 2017 Plan allows for issuance of up to 2.2 shares of common stock. In addition, as of June 30, 2020, the Company may grant additional shares of common stock under the 2017 Plan with up to 0.1 options outstanding under its 2003 Plan and 4.5 options and restricted stock units outstanding under its 2010 Plan, that expire or are cancelled without delivery of shares of common stock. The number of shares, terms, and vesting periods are determined by the Company’s Board of Directors or a committee thereof on an option-by-option basis. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant. In September 2014, the Company began issuing restricted stock units (“RSUs”) in lieu of stock options. RSUs granted to employees generally vest ratably over four years on the anniversary date of the last day of the month in which the RSUs are granted. The number of RSUs awarded to certain executive officers may be reduced if certain additional performance metrics are not met. Options and RSUs granted to the Company’s non-employee directors vest in full upon completion of one year of service on the Board following the date of the grant. Stock Options A summary of option activity is as follows for the fiscal year ended June 30, 2020: Weighted Number average of exercise shares price Options outstanding at beginning of year 5.5 $ 24.45 Options granted — $ — Less: Options exercised (0.4 ) $ 22.56 Options canceled or expired (0.3 ) $ 26.69 Options outstanding at end of year 4.8 $ 24.47 Options exercisable at end of year 4.8 $ 24.47 Options vested and expected to vest 4.8 $ 24.47 There were no options granted during the years ended June 30, 2020, 2019 and 2018. The following table summarizes information about stock options outstanding at June 30, 2020: Options outstanding and exercisable Number Weighted outstanding average Weighted Range of at remaining average exercise June 30, contractual exercise prices 2020 life (years) price 14.88 - 21.29 1.3 1.04 $ 19.09 21.66 - 25.39 0.5 1.33 24.04 26.49 - 26.49 1.5 1.22 26.49 27.07 - 36.55 1.5 2.20 27.18 4.8 1.49 $ 24.47 As of June 30, 2020 there was no unrecognized share-based compensation expense related to stock options. Restricted Stock Units A summary of RSU activity is as follows: 2020 Weighted Number average of grant date shares fair value RSUs outstanding at the beginning of year 2.4 $ 37.70 RSUs granted 1.3 27.96 Less: RSUs released (0.9 ) 35.63 RSUs canceled (0.5 ) 37.80 RSUs outstanding at end of year 2.3 $ 32.50 The weighted average grant-date fair value of restricted stock units grants during the years ended June 30, 2020, 2019 and 2018 was $27.96, $46.62 and $32.67, respectively. The fair value of restricted stock units that vested during the years ended June 30, 2020, 2019 and 2018 was $32.4, $27.6 and $20.4, respectively. As of June 30, 2020, there was $38.2 of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.1 years. We expect all unvested awards to vest and recognize forfeitures as they occur. Share-based compensation expense recognized and included in the Consolidated Statements of Operations for the fiscal years ended June 30, 2020, 2019 and 2018 were as follows: Years Ended June 30, 2020 2019 2018 Cost of molecular diagnostic testing $ 1.2 $ 0.8 $ 0.7 Cost of pharmaceutical and clinical services 0.3 0.2 0.2 Research and development expense 5.0 5.4 4.3 Selling, general, and administrative expense 18.7 27.1 21.9 Total share-based compensation expense $ 25.2 $ 33.5 $ 27.1 The Company has unrecognized share-based compensation cost related to share-based compensation granted under its current plans. The estimated unrecognized share-based compensation cost and related weighted average recognition period, aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows: As of June 30, 2020 Unrecognized share-based compensation cost $ 38.2 Aggregate intrinsic value of options outstanding $ — Aggregate intrinsic value of options fully vested $ — Aggregate intrinsic value of RSUs outstanding $ 25.9 The total intrinsic value of options exercised during 2020, 2019 and 2018 was as follows: Years Ended June 30, 2020 2019 2018 Total intrinsic value of options exercised $ 8.8 $ 0.4 $ 17.0 Employee Stock Purchase Plan On December 5, 2012, following shareholder approval, the Company adopted the 2012 Employee Stock Purchase Plan (the “2012 Purchase Plan”), under which 2.0 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. At June 30, 2020, a total of 1.7 shares of common stock had been purchased under the 2012 Plan. Shares purchased under and compensation expense associated with the 2012 Plan for the years reported are as follows: Years Ended June 30, 2020 2019 2018 Shares purchased under the plans 0.3 0.2 0.1 Plan compensation expense $ 1.7 $ 1.0 $ 0.1 From June 1, 2017 through May 31, 2018 there was an amendment to the 2012 Purchase Plan implemented such that the plan was non-compensatory. As of June 30, 2020, there is $0.7 unrecognized share-based compensation expense related to the 2012 Purchase Plan. The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black‑Scholes option-pricing model using the following weighted-average assumptions: 2020 2019 2018 Risk-free interest rate 1.8% 2.1% 2.1% Expected dividend yield 0% 0% 0% Expected life (in years) 0.5 0.5 0.5 Expected volatility 99% 55% 45%

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	1 1 . INCOME TAXES Income tax benefit consists of the following: Year ended June 30, 2020 2019 2018 Current: Federal $ 26.6 $ (24.2 ) $ 7.7 State 4.9 (0.1 ) 2.2 Foreign 0.5 0.2 — Total current 32.0 (24.1 ) 9.9 Deferred: Federal (51.5 ) 17.8 (22.7 ) State (4.1 ) 1.7 0.7 Foreign (3.6 ) 0.4 (1.4 ) Change in valuation allowance 3.5 (0.2 ) 0.5 Total deferred (55.7 ) 19.7 (22.9 ) Total income tax benefit $ (23.7 ) $ (4.4 ) $ (13.0 ) Income (loss) before income taxes consists of the following: Year ended June 30, 2020 2019 2018 United States $ (240.9 ) $ (0.6 ) $ 122.3 Foreign 17.6 0.6 (2.2 ) Total $ (223.3 ) $ — $ 120.1 The differences between income taxes at the statutory federal income tax rate and income taxes reported in the consolidated statements of operations were as follows: Year ended June 30, 2020 2019 2018 Federal income tax expense at the statutory rate (46.9 ) 21.0 % — 21.0 % 33.7 28.1 % State income taxes, net of federal benefit (0.2 ) 0.1 % 2.0 6422.1 % 2.9 2.4 % Research and development credits, net of the federal tax on state credits (2.8 ) 1.3 % (3.7 ) -11880.9 % (2.1 ) -1.7 % Uncertain tax positions, net of federal benefit 1.9 -0.9 % 2.9 9312.1 % 2.5 2.1 % Uncertain tax benefits statute expired, net of federal benefit (0.4 ) 0.2 % (7.1 ) -22798.5 % — 0.0 % Incentive stock option and employee stock purchase plan expense (0.2 ) 0.1 % (3.1 ) -9954.3 % (1.7 ) -1.4 % Foreign rate differential 0.7 -0.3 % 0.8 2568.8 % (0.8 ) -0.7 % Change in valuation allowance 3.5 -1.7 % (0.2 ) -642.2 % 0.6 0.5 % Tax Cut and Jobs Act impact — 0.0 % — 0.0 % (32.0 ) -26.6 % Fair value adjustments related to acquisition contingent consideration — 0.0 % 0.8 2568.8 % (17.0 ) -14.2 % Non-deductible contingent purchase price and transaction costs (0.3 ) 0.1 % — 0.0 % — 0.0 % Non-deductible meals and entertainment 1.8 -0.8 % 1.3 4174.4 % 0.4 0.3 % Non-deductible officer compensation 1.6 -0.7 % 0.6 1926.6 % — 0.0 % Asset impairment 12.6 -5.6 % — 0.0 % — 0.0 % Expired tax attributes 4.2 -1.9 % — 0.0 % — 0.0 % Non-deductible legal settlement — 0.0 % 1.9 6101.0 % — 0.0 % Foreign disregarded election — 0.0 % 6.4 20550.8 % — 0.0 % Changes in revenue recognition/method — 0.0 % (7.3 ) -23440.8 % — 0.0 % Other, net 0.8 -0.3 % 0.3 963.4 % 0.5 0.5 % (23.7 ) 10.6 % (4.4 ) -14107.7 % (13.0 ) -10.7 % The significant components of the Company’s deferred tax assets and liabilities were comprised of the following: Year ended June 30, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 73.1 $ 85.7 Property, plant and equipment 37.2 — Accrued vacation 1.5 1.2 AR allowance 1.2 3.3 Stock compensation expense 13.8 16.0 Research and development credits 27.6 25.4 Lease right-of-use asset 16.3 — Uncertain state tax positions 1.6 1.3 Other, net 9.6 9.0 Total gross deferred tax assets 181.9 141.9 Less valuation allowance (42.4 ) (38.9 ) Total deferred tax assets 139.5 103.0 Deferred tax liabilities: Intangible assets 150.3 175.4 Lease liability 15.8 — Property, plant and equipment — 2.5 Deferred revenue — 7.7 Total deferred tax liabilities 166.1 185.6 Net deferred tax liability $ (26.6 ) $ (82.6 ) On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was enacted in response to COVID-19 pandemic. The CARES Act made various tax law changes, including among other things (i) increased the limitation under IRC Section 163(j) for 2019 and 2020 to permit additional expensing of interest (ii) enacted technical corrections so that qualified improvement property can be immediately expensed under IRC Section 168(k) and net operating losses arising in tax years beginning in 2017 and ending in 2018 can be carried back two years and carried forward twenty years without a taxable income limitation as opposed to carried forward indefinitely, and (iii) made modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years. The CARES Act did not have a material impact on the results reported for the year ended June 30, 2020. However, the Company is continuing to evaluate the CARES Act’s various tax law changes and the impact they may have on the Company’s results of operations and income tax provision. On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted. The Tax Act makes broad and complex changes to the U.S. tax code that are affecting our fiscal year ending June 30, 2018, including, but not limited to (1) reducing the U.S. federal corporate tax rate from 35 percent to 21 percent; (2) requiring companies to pay a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries; (3) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (4) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (5) creating the base erosion anti-abuse tax (BEAT), a new minimum tax; (6) creating a new limitation on deductible interest expense; (7) revising the rules that limit the deductibility of compensation to certain highly compensated executives, and (8) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017. In connection with the Company’s initial analysis of the impact of the Tax Act and consistent with the requirement to record a provisional estimate when applicable, the Company recorded a discrete net income tax benefit during the quarter ended December 31, 2017 of approximately $32.6 ($0.45 earnings per share increase). This provisional estimate primarily consists of a net benefit for the corporate rate reduction due to the revaluing of net deferred tax liabilities as a result of the reduction in the federal corporate tax rates. The Company’s net deferred tax liabilities represent temporary differences between the book bases of assets which are greater than their tax bases. Upon the reversal of those temporary differences, the future tax impact will be based on the lower federal corporate tax rate enacted by the Tax Act. The Company has now completed its accounting of the income tax effects of the Tax Act. The full impact of the Tax Act is discussed more fully below. The Deemed Repatriation Transition Tax (Transition Tax) is a tax on previously untaxed accumulated and current earnings and profits (E&P) of certain of the Company’s foreign subsidiaries. To determine the amount of the Transition Tax, the Company must determine, in addition to other factors, the amount of post-1986 E&P of the relevant subsidiaries, as well as the amount of non-U.S. income taxes paid on such earnings. The Company has concluded that there was not a material impact during the current or previous fiscal year due to the Transition Tax, as such, no Transition Tax has been recorded. The Company has determined that the provisions of the Tax Act affecting foreign earnings had no effect on the Company’s fiscal year ended June 30, 2018, as the provisions did not apply, and no material effect on the Company’s fiscal year ending June 30, 2019 due to tax elections made by the Company to treat its foreign subsidiaries as disregarded entities. All other foreign provisions were also deemed immaterial or not applicable to the fiscal years ended June 30, 2018, June 30, 2019 and June 30, 2020. As a result of the economic impact of COVID-19, the Company has incurred a cumulative three-year loss. Pursuant to ASU guidance, the negative evidence of a cumulative loss may be difficult to overcome. However, the Company will have significant future taxable income resulting from the reversal of taxable temporary differences. The Company acquired Counsyl, Inc. on July 31, 2018 (see Note 19). As part of the purchase accounting for the acquisition, a net deferred tax liability of approximately $67.6 was recorded, consisting primarily of intangible assets for which the book basis exceeds the tax basis. A corresponding deferred tax asset of $60.7 was recorded, consisting primarily of net operating loss and research credit carryforwards. At June 30, 2020, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated. Subject to Expires Carryforwards Amount sections 382, beginning in year Through Federal net operating loss $ 52.5 Yes 2031 2038 Utah net operating loss 2.7 No 2021 2033 California net operating loss 3.5 No 2027 2040 Other state net operating loss 6.9 Yes 2027 2040 Foreign net operating losses (various jurisdictions) 7.6 No Various Various Federal research credit 11.2 Yes 2027 2040 Utah research credit 11.6 No 2030 2034 California research credit 4.7 No 2027 2040 Texas research credit 0.1 No 2039 2040 Notwithstanding the Deemed Repatriation Tax mentioned above, and consistent with the indefinite reversal criteria of ASC 740-30-25-17, the Company intends to continue to invest undistributed earnings of its foreign subsidiaries indefinitely. Due to the cumulative losses that have been incurred to date in such foreign operations, the amount of unrecorded deferred liability resulting from the indefinite reversal criteria at June 30, 2018 is $0. For those foreign entities for which an election has been made to be treated as disregarded for U.S. tax purposes, the appropriate U.S. jurisdiction deferred tax assets and liabilities have been recorded. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement criteria as set forth in ASC 740. As of June 30, 2020 and 2019, the Company had unrecognized tax benefits of $23.5 and $21.7, respectively. The Company’s gross unrecognized tax benefits as of June 30, 2020 and 2019, and the changes in those balances are as follows: Year ended June 30, 2020 2019 2018 Unrecognized tax benefits at the beginning of year $ 21.7 $ 24.9 $ 25.2 Gross increases - current year tax positions 1.6 2.2 0.6 Gross increases - prior year tax positions 0.7 0.5 2.4 Gross increases - acquisitions — 2.3 — Gross decreases - prior year tax positions — (0.1 ) (3.3 ) Gross decreases - settlements — (2.7 ) — Gross decreases - statute lapse (0.5 ) (5.4 ) — Unrecognized tax benefits at end of year $ 23.5 $ 21.7 $ 24.9 Interest and penalties in year-end balance $ 1.4 $ 0.8 $ 1.5 Interest and penalties related to uncertain tax positions are included as a component of income tax expense and all other interest and penalties are included as a component of other income (expense). The Company files U.S. federal, foreign and state income tax returns in jurisdictions with various statutes of limitations and is subject to examination for the open tax years in the U.S. federal and state jurisdictions of 2015 through 2020 and in the foreign jurisdictions of 2013 through 2020. The Company is currently under audit by the State of New Jersey for the fiscal years June 30, 2013 through 2017; the city of New York for the fiscal years June 30, 2014 through 2016; Germany for the fiscal years June 30, 2013 through 2015; and Switzerland for the fiscal years June 30, 2015 through 2016. Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	1 2 . COMMITMENTS AND CONTINGENCIES The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of June 30, 2020, management of the Company believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows.

Leases

Leases	12 Months Ended
	Jun. 30, 2020
Lessee Disclosure [Abstract]
Leases	13. LEASES The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from one to seven years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options which allows the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These optional periods have not been considered in the determination of the right-of-use-assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the fiscal year ended June 30, 2020, the Company incurred $18.4 in lease costs which are included in operating expenses in the consolidated statement of operations in relation to these operating leases. Of such lease costs, $2.6 was variable lease expense and $0.2 was short-term lease expense, neither of which were included in the measurement of the Company's operating ROU assets and lease liabilities. The variable rent expense is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components. As of June 30, 2020, the maturities of the Company’s operating lease liabilities were as follows: Fiscal year ending: 2021 $ 15.9 2022 14.8 2023 13.6 2024 13.2 2025 10.9 Thereafter 9.6 Total future lease payments 78.0 Less: amounts representing interest (7.6 ) Present value of future lease payments 70.4 Less: current maturities of operating lease liabilities 13.5 Noncurrent operating lease liabilities $ 56.9 As of June 30, 2020, the weighted average remaining lease term is 5.3 years and the weighted average discount rate used to determine the operating lease liability was 3.87%. Disclosures related to periods prior to the adoption of ASU 2016-02 The total rent expense of the Company for the fiscal years ended June 30, 2019 and 2018 was $19.7 and $15.5, respectively. Future minimum lease payments required under noncancelable operating leases that have initial or remaining noncancelable lease term in excess of one year at June 30, 2019 are as follows: Fiscal year ending: 2020 $ 15.1 2021 14.1 2022 13.1 2023 12.2 2024 11.9 Thereafter 19.1 $ 85.5

Employee Deferred Savings Plan

Employee Deferred Savings Plan	12 Months Ended
	Jun. 30, 2020
Postemployment Benefits [Abstract]
Employee Deferred Savings Plan	1 4 . EMPLOYEE DEFERRED SAVINGS PLAN The Company has a deferred savings plan which qualifies under Section 401(k) of the Internal Revenue Code. Substantially all of the Company’s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee’s contribution with the employer’s contribution not to exceed 4% of the employee’s compensation. The Company temporarily suspended matching contributions effective April 16, 2020 for 90 days, matching contributions were subsequently resumed effective July 16, 2020. The Company’s recorded contributions to the plan for the fiscal years reported are as follows: Years Ended June 30, 2020 2019 2018 Deferred savings plan contributions $ 7.1 $ 8.3 $ 7.2

Segment and Related Information

Segment and Related Information	12 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Segment and Related Information	1 5 . SEGMENT AND RELATED INFORMATION The Company’s business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (Note 1). The Company evaluates segment performance based on income (loss) before interest income and other income and expense. Diagnostics Other Total Year ended June 30, 2020: Revenues $ 593.5 $ 45.1 $ 638.6 Depreciation and amortization 68.2 3.8 72.0 Segment operating loss (82.4 ) (149.3 ) (231.7 ) Year ended June 30, 2019: Revenues $ 789.4 $ 61.7 $ 851.1 Depreciation and amortization 67.7 5.3 73.0 Segment operating income (loss) 133.3 (125.7 ) 7.6 Year ended June 30, 2018: Revenues $ 690.4 $ 53.3 $ 743.7 Depreciation and amortization 49.2 5.2 54.4 Segment operating income (loss) 142.6 (20.7 ) 121.9 Years Ended June 30, 2020 2019 2018 Total operating income (loss) for reportable segments $ (231.7 ) $ 7.6 $ 121.9 Unallocated amounts: Interest income 3.0 3.2 1.8 Interest expense (10.8 ) (12.0 ) (3.2 ) Other 16.2 1.2 (0.4 ) Income (loss) from operations before income taxes (223.3 ) — 120.1 Income tax benefit (23.7 ) (4.4 ) (13.0 ) Net income (loss) (199.6 ) 4.4 133.1 Net loss attributable to non-controlling interest (0.1 ) (0.2 ) (0.2 ) Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (199.5 ) $ 4.6 $ 133.3 The following table sets forth a comparison of balance sheet assets by operating segment: June 30, 2020 2019 Net equipment, leasehold improvements and property: Diagnostics $ 23.9 $ 25.7 Other 13.1 31.6 Total $ 37.0 $ 57.3 Total Assets: Diagnostics $ 1,002.8 $ 1,215.6 Other 147.0 155.3 Total $ 1,149.8 $ 1,370.9 The following table reconciles assets by geographical region: June 30, 2020 2019 Net equipment, leasehold improvements and property: United States $ 35.4 $ 36.0 Rest of world 1.6 21.3 Total $ 37.0 $ 57.3 Total Assets: United States $ 1,097.2 $ 1,265.8 Rest of world 52.6 105.1 Total $ 1,149.8 $ 1,370.9 The following table reconciles assets by operating segment and geographic region to total assets: June 30, 2020 2019 Total assets by segment and geographical region $ 1,149.8 $ 1,370.9 Cash, cash equivalents, and marketable investment securities (1) 254.8 191.8 Total $ 1,404.6 $ 1,562.7 (1) The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments. The majority of the Company’s revenues were derived from the sale of diagnostic tests in the United States.

Sale of Subsidiary

Sale of Subsidiary	12 Months Ended
	Jun. 30, 2020
Discontinued Operations And Disposal Groups [Abstract]
Sale of Subsidiary	1 6 . SALE OF SUBSIDIARY On February 28, 2020, the Company closed the sale of the Clinic with Landkreis Starnberg. As a result of the sale, the Clinic was deconsolidated from the Company’s consolidated financial statements in accordance with ASC 810. The Company recorded a pre-tax net gain of $1.0 on the sale, which is recorded in other income in the Company’s Consolidated Statements of Operations. The gain recorded consists of a pre-tax gain of $1.2 associated with the settlement of the Clinic pension, offset by a loss of $0.2 due to the difference between the purchase price and net assets as well as the effects of foreign currency. The Clinic was previously reported as part of the Company’s other segment.

Business Acquisitions

Business Acquisitions	12 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Business Acquisitions	17 . Counsyl On July 31, 2018, the Company completed the acquisition of Counsyl, Inc. (“Counsyl”), a leading provider of genetic testing and DNA analysis services, pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated May 25, 2018. Pursuant to the terms of the Merger Agreement, Myriad Merger Sub, Inc., a newly created wholly-owned subsidiary of the Company, was merged with and into Counsyl, with Counsyl continuing as the surviving corporation and a wholly-owned subsidiary of Myriad. The Company believes the acquisition allows for further entry into the high-growth reproductive testing market, with the ability to become a leader in women’s health genetic testing. The Company acquired Counsyl for total consideration of $405.9, consisting of $278.5 in cash, financed in part by the Amendment No. 1 to the Facility (see Note 7) and 2,994,251 shares of common stock issued, valued at $127.4. The shares were issued and valued as of July 31, 2018 at a per share market closing price of $42.53. Of the cash consideration, $5.0 was deposited into an escrow account to fund any post-closing adjustments payable to Myriad based upon differences between the estimated working capital and the actual working capital of Counsyl at closing. The working capital was finalized during the second quarter as described below. Consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The significant assumptions used in the model to estimate the value of the intangible assets included projected cash flows, discount rates, net working capital and long-term growth rate. The initial allocation of the consideration transferred is based on a preliminary valuation and is subject to adjustments. Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible), liabilities assumed, as well as tax-related matters. During the measurement period, the Company may record adjustments to the provisional amounts recognized. During the year ended June 30, 2019, $1.1 of this escrow was returned to Myriad as a result of a working capital adjustment which reduced the total consideration and goodwill. There was also a reduction in the intangible assets of $2.9 due to updated assumptions related to contributory asset charges associated with the related acquired asset, a $1.9 decrease in the deferred tax liability, Estimated Fair Value Current assets $ 42.5 Intangible assets 290.0 Equipment 18.2 Other assets 0.1 Goodwill 99.3 Current liabilities (19.6 ) Long term liabilities (0.1 ) Deferred tax liability (9.2 ) Total fair value purchase price $ 421.2 Less: Cash acquired (15.3 ) Total consideration transferred $ 405.9 Identifiable Intangible Assets The Company acquired intangible assets that consisted of developed screening processes, which had an estimated fair value of $290.0. The fair values of these developed screening processes and related useful lives were determined using a probability-weighted income approach that discounts expected future cash flows to present value. The estimated net cash flows were discounted using a discount rate of 12.5%, which is based on the estimated internal rate of return for the acquisition and represents the rate that market participants might use to value the intangible assets. The Company will amortize the intangible assets on a straight-line basis over their estimated useful lives of 12 years. Goodwill The goodwill represents the excess of consideration transferred over the fair value of assets acquired and liabilities assumed and is attributable to the benefits expected from combining the Company’s expertise with Counsyl’s technology, customer insights, and ability to effectively integrate genetic screening into clinical practice with OBGYNs. Changes in goodwill since the initial purchase are shown below: Carrying amount Balance September 30, 2018 $ 94.9 Fair value adjustment to equipment 0.7 Intangible adjustment 2.9 Working capital adjustment (1.1 ) Change in deferred tax liability 1.9 Ending balance June 30, 2020 $ 99.3 This goodwill is not deductible for income tax purposes. Pro Forma Information (Unaudited) The unaudited pro-forma results presented below include the effects of the Counsyl acquisition as if it had been consummated as of July 1, 2017, with adjustments to give effect to pro forma events that are directly attributable to the acquisition, which includes adjustments related to the amortization of acquired intangible assets, interest income and expense, and depreciation. The unaudited pro forma results do not reflect any operating efficiency or potential cost savings that may result from the consolidation of Counsyl with the Company. Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations and are not necessarily indicative of results that might have been achieved had the acquisition been consummated as of July 1, 2017. Year Ended Year Ended June 30, June 30, 2019 2018 Revenue $ 861.3 $ 881.8 Income from operations 17.9 74.3 Net income 13.8 73.0 Net income per share, basic $ 0.19 $ 1.01 Net income per share, diluted $ 0.18 $ 0.98 To complete the purchase transaction, the Company incurred approximately $6.8 of acquisition costs, which are recorded as selling, general and administrative expenses in the period incurred. For the year ended June 30, 2019, Counsyl contributed revenue of approximately $104.9. For the year ended June 30, 2019, operating expenses related to Counsyl were approximately $67.6.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Jun. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	18. SUPPLEMENTAL CASH FLOW INFORMATION Years Ended June 30, 2020 2019 2018 Cash paid for income taxes $ 1.0 $ 6.5 $ 11.7 Cash paid for interest 9.5 11.6 3.0 Non-cash investing and financing activities: Fair value adjustment on marketable investment securities recorded to stockholders' equity 0.7 1.2 (0.4 ) Establishment of operation lease right-of-use assets and lease liabilities Operating lease right-of-use assets $ 74.5 — — Operating lease liabilities (78.8 ) — — Accrued liabilities and other long-term liabilities 4.3 — —

Supplementary Quarterly Financi

Supplementary Quarterly Financial Data (Unaudited)	12 Months Ended
	Jun. 30, 2020
Quarterly Financial Data [Abstract]
Supplementary Quarterly Financial Data (Unaudited)	1 9 . SUPPLEMENTARY QUARTERLY FINANCIAL DATA (UNAUDITED) In millions, except per share amounts Quarters Ended Jun 30, Mar 31, Dec 31, Sep 30, Consolidated Statement of Operations Data: 2020 2020 2019 (a) 2019 Molecular diagnostic testing $ 83.3 $ 150.5 $ 181.1 $ 172.0 Pharmaceutical and clinical services 9.9 13.5 14.0 14.3 Total revenue 93.2 164.0 195.1 186.3 Costs and expenses: Cost of molecular diagnostic testing 32.2 43.1 41.0 41.2 Cost of pharmaceutical and clinical services 4.5 7.0 8.6 8.5 Research and development expense 17.4 19.7 18.8 21.3 Change in the fair value of contingent consideration — (3.4 ) (0.1 ) 0.7 Selling, general and administrative expense 107.4 132.9 134.3 135.5 Goodwill and intangible asset impairment charges — 98.4 1.3 — Total costs and expenses 161.5 297.7 203.9 207.2 Operating loss (68.3 ) (133.7 ) (8.8 ) (20.9 ) Other income (expense): Interest income 0.5 0.8 0.8 0.9 Interest expense (3.1 ) (2.3 ) (2.5 ) (2.9 ) Other 12.4 4.1 (0.9 ) 0.6 Total other income (expense) 9.8 2.6 (2.6 ) (1.4 ) Loss before income taxes (58.5 ) (131.1 ) (11.4 ) (22.3 ) Income tax benefit (3.0 ) (15.9 ) (3.1 ) (1.7 ) Net loss (55.5 ) (115.2 ) (8.3 ) (20.6 ) Net loss attributable to non-controlling interest (0.1 ) — — — Net loss attributable to Myriad Genetics, Inc. stockholders $ (55.4 ) $ (115.2 ) $ (8.3 ) $ (20.6 ) Loss per share: Basic $ (0.74 ) $ (1.55 ) $ (0.11 ) $ (0.28 ) Diluted $ (0.74 ) $ (1.55 ) $ (0.11 ) $ (0.28 ) Weighted average shares outstanding: Basic 74.6 74.5 74.4 73.7 Diluted 74.6 74.5 74.4 73.7 (a) An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period. In millions, except per share amounts Quarters Ended Jun 30, Mar 31, Dec 31, Sep 30, Consolidated Statement of Operations Data: 2019 2019 2018 2018 Molecular diagnostic testing $ 196.9 $ 200.5 $ 203.0 $ 189.0 Pharmaceutical and clinical services 18.5 16.1 13.8 13.3 Total revenue 215.4 216.6 216.8 202.3 Costs and expenses: Cost of molecular diagnostic testing 41.6 40.3 44.0 42.3 Cost of pharmaceutical and clinical services 9.0 8.3 8.1 7.4 Research and development expense 20.9 21.5 22.4 21.1 Change in contingent consideration (0.3 ) — 1.0 0.4 Selling, general and administrative expense 149.8 140.6 135.2 129.9 Total costs and expenses 221.0 210.7 210.7 201.1 Operating income (loss) (5.6 ) 5.9 6.1 1.2 Other income (expense): Interest income 0.9 0.7 0.9 0.7 Interest expense (3.2 ) (3.2 ) (3.4 ) (2.2 ) Other 0.2 (0.1 ) — 1.1 Total other income (expense) (2.1 ) (2.6 ) (2.5 ) (0.4 ) Income (loss) before income taxes (7.7 ) 3.3 3.6 0.8 Income tax provision (benefit) (3.4 ) (3.6 ) 1.0 1.6 Net income (loss) (4.3 ) 6.9 2.6 (0.8 ) Net loss attributable to non-controlling interest (0.1 ) — — (0.1 ) Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (4.2 ) $ 6.9 $ 2.6 $ (0.7 ) Earnings (loss) per share: Basic $ (0.06 ) $ 0.09 $ 0.04 $ (0.01 ) Diluted $ (0.06 ) $ 0.09 $ 0.03 $ (0.01 ) Weighted average shares outstanding: Basic 73.4 73.3 74.2 73.0 Diluted 74.8 74.9 76.5 73.0

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Financial Statement Presentation	Basis of Financial Statement Presentation Myriad Genetics, Inc. and subsidiaries (collectively, the Company) is a leading personalized precision medicine company acting as a trusted advisor to transform patient lives through pioneering molecular diagnostics. The Company employs a number of proprietary technologies, including DNA, RNA and protein analysis, that help it to understand the genetic basis of human disease and the role that genes and their related proteins may play in the onset and progression of disease. The Company uses this information to guide the development of new molecular diagnostic and companion diagnostic tests that are designed to assess an individual’s risk for developing disease later in life (predictive medicine), identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment (personalized medicine), or assess a patient’s risk of disease progression and disease recurrence (prognostic medicine). The Company generates revenue by performing molecular diagnostic tests as well as by providing pharmaceutical and clinical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters are located in Salt Lake City, Utah. The accompanying consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company” or “Myriad”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with U.S. GAAP.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires Company management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include the carrying amount of fixed assets, valuation allowances for receivables and deferred income tax assets, certain accrued liabilities, share-based compensation, valuation of intangible assets from acquisitions and impairment analysis of goodwill and intangible assets. Actual results could differ from those estimates. The full impact of the COVID-19 outbreak continues to evolve and its future impacts remain highly uncertain and unpredictable. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for future periods.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s account receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 15%, 14% and 17% of total revenue for the fiscal years ended June 30, 2020, 2019 and 2018, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. No
Marketable Investment Securities	Marketable Investment Securities The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company’s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash. A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against “Other income” when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company’s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the fiscal years ended June 30, 2020, 2019 and 2018.
Inventory	Inventory Inventories consist of reagents, plates and testing kits. Inventories are stated at the lower of cost or market on a first-in, first-out basis. In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company evaluates its inventories for excess quantities and obsolescence. Inventories that are considered obsolete are expensed. The valuation of inventories requires the use of estimates as to the amounts of current inventories that will be sold. These estimates are dependent on management’s assessment of current and expected orders from the Company’s customers.
Trade Accounts Receivable	Trade Accounts Receivable Trade accounts receivable represents amounts billed to customers for revenue recognized related to molecular diagnostic tests and pharmaceutical and clinical services. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.
Property, Plant and Equipment	Property, Plant and Equipment Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful lives or the associated lease terms, which range from three to seven years. Repairs and maintenance costs are charged to expense as incurred.
Intangible Assets and Other Long-Lived Assets	Intangible Assets and Other Long-Lived Assets Intangible and other long-lived assets are comprised of acquired licenses, technology and intellectual property and purchased in-process research and development. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The estimated useful life of acquired in-process research and development was also evaluated in conjunction with the annual impairment analysis of intangible assets. The classification of the Company’s acquired in-process research and development as an indefinite lived asset was deemed appropriate as the related research and development was not yet complete nor had it been abandoned. The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Goodwill	Goodwill Goodwill is tested for impairment by reporting unit on an annual basis as of April 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators and competition. Impairment of goodwill is first assessed using a qualitative approach. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed. The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.
Revenue Recognition	Revenue Recognition In May 2014, The Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted this standard as of July 1, 2018, utilizing the full retrospective method of adoption allowed by the standard, in order to provide for comparative results in all periods presented. The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally customers make payments prior to the Company's performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During 2020, the Company received approximately $29.7 in advance Medicare payments as part of the CARES Act, which was enacted on March 27, 2020 to provide relief from the economic impacts of COVID-19. The advance Medicare payments are included in prepayments of deferred revenue. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below: Years Ended June 30, 2020 2019 Deferred revenue - beginning balance $ 2.2 $ 2.6 Revenue recognized (7.2 ) (7.9 ) Prepayments 37.8 7.5 Deferred revenue - ending balance $ 32.8 $ 2.2 Myriad generates revenue by performing molecular diagnostic testing and pharmaceutical and clinical services. Revenue from the sale of molecular diagnostic tests and pharmaceutical and clinical services is recorded at the estimated transaction price. The Company has determined that the communication of test results or the completion of clinical and pharmaceutical services indicates transfer of control for revenue recognition purposes. In accordance with ASU 2014-09, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, periodically the Company enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical and clinical services that may have terms longer than one year and include multiple performance obligations. As of June 30, 2020, the aggregate amount of the transaction price of such contracts that is allocated to the remaining performance obligations is $2.7. The Company provides financial assistance programs to its patients and volume discounts to payors. In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collection from third-party payors. An estimate of transaction price does not include any estimated amount of variable consideration that are constrained. The Company applies the expected value method for sales where the Company has a large number of contracts with similar characteristics. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value under the new standard, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. In accordance with Accounting Standards Update No. 2016-02, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), the Company has elected to exclude from the measurement of transaction price, all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for e.g. sales tax, value added tax etc. During the three and twelve months ended June 30, 2020, the Company recognized a $0.4 decrease and $9.9 decrease in revenue, respectively, which resulted in no impact to earnings (loss) per share for the three months ended June 30, 2020 and a $(0.10) impact to earnings (loss) per share for the twelve months ended June 30, 2020, for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. During the fourth quarter of fiscal year 2020, the Company identified an error related to prior periods for Medicare claims and has reduced revenue and recorded an accrued liability for a total of $4.7 million that will be refunded to Medicare. The impact of correcting the error in the current period and the impact to all prior periods was concluded to be immaterial. The correction of the error in the current period resulted in an impact to earnings (loss) per share for the three and twelve months ended June 30, 2020 of $ (0.05) The Company has elected to apply the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company has also elected to apply the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and vast majority of payments terms have a payback period of less than one year. The following table represents the Company’s revenue by type for the years ended June 30, 2020, 2019, and 2018: Years Ended June 30, (In millions) 2020 2019 2018 Molecular diagnostic revenues: Hereditary Cancer Testing $ 347.4 $ 479.7 $ 471.4 GeneSight 74.1 112.6 124.9 Prenatal 76.7 104.9 — Vectra 39.1 48.3 55.2 Prolaris 24.7 25.5 21.5 EndoPredict 10.5 10.4 8.8 Other 14.4 8.0 8.6 Total molecular diagnostic revenue 586.9 789.4 690.4 Pharmaceutical and clinical service revenue 51.7 61.7 53.3 Total revenue $ 638.6 $ 851.1 $ 743.7
Share-based payment expense	Share-based payment expense We recognize the fair value compensation cost relating to share-based payment transactions in accordance with Accounting Standards Codification (“ASC”) 718, Compensation – Stock Compensation. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee’s requisite service period, which is generally the vesting period. The fair value of restricted stock units is based on the number of shares granted and the quoted price of the Company’s common stock on the grant date. Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of our stock price.
Other Income	Other Income The Company recognizes stimulus or grant payments that it receives that do not need to be paid back as other income. During the year ended June 30, 2020, the Company received approximately $14.6 from the Provider Relief Fund under the CARES Act to reimburse the Company for health care related expenses or lost revenues that are attributable to COVID-19, which is recognized as a component of other income in the consolidated statements of operations.
Income Taxes	Income Taxes The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company’s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial condition, results of operations or cash flows.
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Years Ended June 30, 2020 2019 2018 Denominator: Weighted-average shares outstanding used to compute basic EPS 74.3 73.5 69.4 Effect of dilutive stock options — 2.5 2.6 Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 74.3 76.0 72.0 Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Years Ended June 30, 2020 2019 2018 Anti-dilutive options and RSUs excluded from EPS computation 5.5 0.8 —
Foreign Currency	Foreign Currency The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in accumulated other comprehensive loss as a separate component of stockholders’ equity. The following table shows the cumulative translation adjustments included in accumulated other comprehensive loss: Ending balance June 30, 2019 $ (7.2 ) Period translation adjustments (0.6 ) Reclassification upon deconsolidation of subsidiary 1.3 Ending balance June 30, 2020 $ (6.5 ) Transaction gains and losses are included in the determination of net income (loss) in the consolidated statements of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Standards Effective in Future Years and Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) (“ASU 2016-13”) which introduces new guidance for the accounting for credit losses on certain instruments within its scope. ASU 2016-13 introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. For trade receivables, the Company will be required to use a forward-looking expected loss model rather than the incurred loss model for recognizing credit losses, which reflects losses that are probable. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. ASU 2016-13 is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. Early application of the guidance is permitted for all entities for fiscal years beginning after December 15, 2018, including the interim periods within those fiscal years. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. The Company will adopt ASU 2016-13 on July 1, 2020 and does not expect the adoption to have a material impact on its consolidated financial statements or financial statement disclosures. In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software, including hosting arrangements that include an internal-use software license. This guidance is effective for public entities for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years, with early adoption permitted. The Company will adopt ASU 2018-15 on July 1, 2020 on a prospective basis and expects the adoption will result in amounts related to implementation costs that were previously expensed to be capitalized on the balance sheet. Recently Adopted Standards In February 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and changing certain lessor accounting requirements. ASU 2016-02 also requires entities to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. On July 1, 2019, the Company adopted ASU 2016-02 under the modified retrospective approach by initially applying ASU 2016-02 at the adoption date, rather than at the beginning of the earliest comparative period presented. Results for the fiscal year ended June 30, 2020 are presented under ASU 2016-02. Prior period amounts were not adjusted and continue to be reported under previous lease accounting guidance. Under ASU 2016-02, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company’s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term. ASU 2016-02 provides a number of optional practical expedients in transitioning to ASU 2016-02. The Company has elected the package of practical expedients to avoid reassessing under ASU 2016-02 prior conclusions about lease identification, lease classification and initial direct costs. The Company has also elected the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use ROU assets based on all facts and circumstances through the effective date of the new standard. ASU 2016-02 also provides practical expedients for ongoing lease accounting. The Company has elected the recognition exemption for short-term leases for all leases that qualify. Under this exemption, the Company will not recognize ROU assets or lease liabilities for those leases that qualify as a short-term lease (leases with lease terms of 12 months or less), which includes not recognizing ROU assets or lease liabilities for existing short-term leases in transition. The Company also has elected the practical expedient to avoid separating lease and non-lease components for any of its leases within its existing classes of assets. As of the July 1, 2019 adoption date, the Company recognized operating lease liabilities of $78.8 and right-of-use assets related to operating leases totaling $74.5 as of the adoption date. These are presented as “Current maturities of operating lease liabilities” for a total of $13.1, “Noncurrent operating lease liabilities” for a total of $65.7, and “Operating lease right-of-use assets” for a total of $74.5 on the Company’s consolidated balance sheet. No adjustments to the beginning retained earnings balance were required. On October 1, 2019, the Company early adopted ASU 2017-04, Intangibles – Goodwill and Other (Topic 350) (“ASU 2017-04”) as permitted under the standard. The standard simplifies the accounting for goodwill impairment by requiring a goodwill impairment to be measured using a single step impairment model, whereby the impairment equals the difference between the carrying amount and the fair value of the specified reporting units as a whole. This eliminates the second step of the current impairment model that requires a company to first estimate the fair value of all assets in a reporting unit and measure impairments based on those fair values and a residual measurement approach. The standard also specifies that any loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This ASU was adopted on a prospective basis with no material impact to the Company’s consolidated financial statements.

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2020
Reconciliation of Deferred Revenue Balances	A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below: Years Ended June 30, 2020 2019 Deferred revenue - beginning balance $ 2.2 $ 2.6 Revenue recognized (7.2 ) (7.9 ) Prepayments 37.8 7.5 Deferred revenue - ending balance $ 32.8 $ 2.2
Schedule of Company's Revenue by Type	The following table represents the Company’s revenue by type for the years ended June 30, 2020, 2019, and 2018: Years Ended June 30, (In millions) 2020 2019 2018 Molecular diagnostic revenues: Hereditary Cancer Testing $ 347.4 $ 479.7 $ 471.4 GeneSight 74.1 112.6 124.9 Prenatal 76.7 104.9 — Vectra 39.1 48.3 55.2 Prolaris 24.7 25.5 21.5 EndoPredict 10.5 10.4 8.8 Other 14.4 8.0 8.6 Total molecular diagnostic revenue 586.9 789.4 690.4 Pharmaceutical and clinical service revenue 51.7 61.7 53.3 Total revenue $ 638.6 $ 851.1 $ 743.7
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Years Ended June 30, 2020 2019 2018 Denominator: Weighted-average shares outstanding used to compute basic EPS 74.3 73.5 69.4 Effect of dilutive stock options — 2.5 2.6 Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 74.3 76.0 72.0
Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation	These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows: Years Ended June 30, 2020 2019 2018 Anti-dilutive options and RSUs excluded from EPS computation 5.5 0.8 —
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss	The following table shows the cumulative translation adjustments included in accumulated other comprehensive loss: Ending balance June 30, 2019 $ (7.2 ) Period translation adjustments (0.6 ) Reclassification upon deconsolidation of subsidiary 1.3 Ending balance June 30, 2020 $ (6.5 )

Marketable Investment Securit_2

Marketable Investment Securities (Tables)	12 Months Ended
	Jun. 30, 2020
Investments Debt And Equity Securities [Abstract]
Schedule of Fair Value Debt Securities Classified as Available-for-Sale Securities by Major Security Type and Class of Security	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value debt securities classified as available-for-sale securities by major security type and class of security at June 30, 2020 and 2019 were as follows: Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At June 30, 2020: Cash and cash equivalents: Cash $ 132.8 $ — $ — $ 132.8 Cash equivalents 30.9 — — 30.9 Total cash and cash equivalents 163.7 — — 163.7 Available-for-sale: Corporate bonds and notes 50.1 0.8 — 50.9 Municipal bonds 17.8 0.2 — 18.0 Federal agency issues 5.5 0.1 — 5.6 US government securities 16.4 0.2 — 16.6 Total $ 253.5 $ 1.3 $ — $ 254.8 Gross Gross unrealized unrealized Amortized holding holding Estimated cost gains losses fair value At June 30, 2019: Cash and cash equivalents: Cash $ 68.7 $ — $ — $ 68.7 Cash equivalents 24.5 — — 24.5 Total cash and cash equivalents 93.2 — — 93.2 Available-for-sale: Corporate bonds and notes 64.0 0.6 — 64.6 Municipal bonds 15.3 — — 15.3 Federal agency issues 9.0 — — 9.0 US government securities 9.7 — — 9.7 Total $ 191.2 $ 0.6 $ — $ 191.8
Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale are as follows at June 30, 2020: Amortized Estimated cost fair value Cash 132.8 132.8 Cash equivalents 30.9 30.9 Available-for-sale: Due within one year 53.7 54.1 Due after one year through five years 36.1 37.0 Due after five years — — Total $ 253.5 $ 254.8

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities	The following tables set forth the fair value of the Company’s financial assets and liabilities that are re-measured on a regular basis: Level 1 Level 2 Level 3 Total June 30, 2020 Money market funds (a) $ 30.9 $ — $ — $ 30.9 Corporate bonds and notes — 50.9 — 50.9 Municipal bonds — 18.0 — 18.0 Federal agency issues — 5.6 — 5.6 US government securities — 16.6 — 16.6 Contingent consideration — — (6.8 ) (6.8 ) Total $ 30.9 $ 91.1 $ (6.8 ) $ 115.2 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. Level 1 Level 2 Level 3 Total June 30, 2019 Money market funds (a) $ 17.2 $ — $ — $ 17.2 Corporate bonds and notes 2.5 64.4 — 66.9 Municipal bonds — 15.4 — 15.4 Federal agency issues — 9.0 — 9.0 US government securities — 9.8 — 9.8 Contingent consideration — — (13.8 ) (13.8 ) Total $ 19.7 $ 98.6 $ (13.8 ) $ 104.5 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest.
Change in Fair Value of Contingent Consideration	The following table reconciles the change in the fair value of the contingent consideration during the periods presented: Carrying Amount Balance June 30, 2019 $ 13.8 Payment of contingent consideration (3.9 ) Change in fair value recognized in the statement of operations (2.8 ) Translation adjustments recognized in other comprehensive income (0.3 ) Balance June 30, 2020 $ 6.8

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	Years Ended June 30, 2020 2019 Land $ — $ 2.3 Buildings and improvements — 18.8 Leasehold improvements 31.8 31.0 Equipment 112.1 117.1 143.9 169.2 Less accumulated depreciation (106.9 ) (111.9 ) Property, plant and equipment, net $ 37.0 $ 57.3 During the third quarter of fiscal year 2020, the Company sold the Clinic resulting in the deconsolidation of $19.5 of the balance of property, plant and equipment. See Note 16 for additional information regarding the sale of the Clinic. Years Ended June 30, 2020 2019 2018 Depreciation expense $ 11.0 $ 13.7 $ 17.1

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the years ended June 30, 2020 and 2019 are as follows: Diagnostic Other Total Years Ended June 30, Years Ended June 30, Years Ended June 30, 2020 2019 2020 2019 2020 2019 Beginning balance $ 351.6 $ 252.8 $ 65.6 $ 65.8 $ 417.2 $ 318.6 Acquisitions (see note 19) — 94.9 — — — 94.9 Adjustments to acquisitions (see note 19) — 4.4 — — — 4.4 Goodwill deconsolidated on sale of Clinic — — (7.3 ) — (7.3 ) — Goodwill impairment charge (80.7 ) — (1.3 ) — (82.0 ) — Translation adjustments (0.2 ) (0.5 ) (0.1 ) (0.2 ) (0.3 ) (0.7 ) Ending balance $ 270.7 $ 351.6 $ 56.9 $ 65.6 $ 327.6 $ 417.2
Summarized Amounts Reported as Intangible Assets	The following summarizes the amounts reported as intangible assets: Gross Carrying Accumulated At June 30, 2020: Amount Amortization Net Purchased licenses and technologies $ 815.6 $ (217.1 ) $ 598.5 Customer relationships 4.6 (4.2 ) 0.4 Trademarks 3.0 (1.4 ) 1.6 Total amortizable intangible assets 823.2 (222.7 ) 600.5 In-process research and development 4.8 — 4.8 Total unamortized intangible assets 4.8 — 4.8 Total intangible assets $ 828.0 $ (222.7 ) $ 605.3 Gross Carrying Accumulated At June 30, 2019: Amount Amortization Net Purchased licenses and technologies $ 815.7 $ (156.6 ) $ 659.1 Customer relationships 4.6 (3.8 ) 0.8 Trademarks 3.0 (1.2 ) 1.8 Total amortizable intangible assets 823.3 (161.6 ) 661.7 In-process research and development 23.0 — 23.0 Total unamortized intangible assets 23.0 — 23.0 Total intangible assets $ 846.3 $ (161.6 ) $ 684.7
Amortization for Intangible Assets	The Company recorded amortization during the respective periods for these intangible assets as follows: Years Ended June 30, 2020 2019 2018 Amortization of intangible assets $ 61.0 $ 59.3 $ 37.3

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Jun. 30, 2020
Payables And Accruals [Abstract]
Summary of Accrued Liabilities	Years Ended June 30, 2020 2019 Employee compensation and benefits $ 47.4 $ 48.8 Accrued taxes payable 6.1 3.0 Qui tam settlement — 9.1 Other 22.4 18.0 Total accrued liabilities $ 75.9 $ 78.9

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Amounts outstanding under the Amended Facility were as follows: Years Ended June 30, 2020 2019 Long-term debt $ 226.7 $ 235.0 Long-term debt discount (2.3 ) (1.5 ) Net long-term debt $ 224.4 $ 233.5

Other Long Term Liabilities (Ta

Other Long Term Liabilities (Tables)	12 Months Ended
	Jun. 30, 2020
Other Liabilities Disclosure [Abstract]
Summary of Other Long Term Liabilities	Years Ended June 30, 2020 2019 Pension obligation $ — $ 6.8 Other 4.3 1.0 Total other long-term liabilities $ 4.3 $ 7.8

Preferred and Common Stockhol_2

Preferred and Common Stockholder's Equity (Tables)	12 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Summary of Common Shares Issued and Outstanding	Common shares issued and outstanding Years Ended June 30, 2020 2019 2018 Common stock issued and outstanding at July 1 73.5 70.6 68.4 Common stock issued upon exercise of options and employee stock plans 1.2 4.5 2.2 Repurchase and retirement of common stock — (1.6 ) — Common stock issued and outstanding at June 30 74.7 73.5 70.6
Schedule of Stock Repurchases	The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to retained earnings/accumulated deficit for the repurchases for periods ended June 30, 2020, 2019 and 2018 were as follows: Year ended June 30, 2020 2019 2018 Shares purchased and retired — 1.6 — Common stock and additional paid-in-capital reductions $ — $ 16.9 $ — Charges to retained earnings $ — $ 33.1 $ —

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2020
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding	A summary of option activity is as follows for the fiscal year ended June 30, 2020: Weighted Number average of exercise shares price Options outstanding at beginning of year 5.5 $ 24.45 Options granted — $ — Less: Options exercised (0.4 ) $ 22.56 Options canceled or expired (0.3 ) $ 26.69 Options outstanding at end of year 4.8 $ 24.47 Options exercisable at end of year 4.8 $ 24.47 Options vested and expected to vest 4.8 $ 24.47
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding and Exercisable	The following table summarizes information about stock options outstanding at June 30, 2020: Options outstanding and exercisable Number Weighted outstanding average Weighted Range of at remaining average exercise June 30, contractual exercise prices 2020 life (years) price 14.88 - 21.29 1.3 1.04 $ 19.09 21.66 - 25.39 0.5 1.33 24.04 26.49 - 26.49 1.5 1.22 26.49 27.07 - 36.55 1.5 2.20 27.18 4.8 1.49 $ 24.47
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding	A summary of RSU activity is as follows: 2020 Weighted Number average of grant date shares fair value RSUs outstanding at the beginning of year 2.4 $ 37.70 RSUs granted 1.3 27.96 Less: RSUs released (0.9 ) 35.63 RSUs canceled (0.5 ) 37.80 RSUs outstanding at end of year 2.3 $ 32.50
Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations	Share-based compensation expense recognized and included in the Consolidated Statements of Operations for the fiscal years ended June 30, 2020, 2019 and 2018 were as follows: Years Ended June 30, 2020 2019 2018 Cost of molecular diagnostic testing $ 1.2 $ 0.8 $ 0.7 Cost of pharmaceutical and clinical services 0.3 0.2 0.2 Research and development expense 5.0 5.4 4.3 Selling, general, and administrative expense 18.7 27.1 21.9 Total share-based compensation expense $ 25.2 $ 33.5 $ 27.1
Schedule of Unrecognized Share-Based Compensation Cost	The Company has unrecognized share-based compensation cost related to share-based compensation granted under its current plans. The estimated unrecognized share-based compensation cost and related weighted average recognition period, aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows: As of June 30, 2020 Unrecognized share-based compensation cost $ 38.2 Aggregate intrinsic value of options outstanding $ — Aggregate intrinsic value of options fully vested $ — Aggregate intrinsic value of RSUs outstanding $ 25.9
Schedule of Intrinsic Value of Options Exercised	The total intrinsic value of options exercised during 2020, 2019 and 2018 was as follows: Years Ended June 30, 2020 2019 2018 Total intrinsic value of options exercised $ 8.8 $ 0.4 $ 17.0
Schedule of Shares Purchased and Compensation Expenses	Shares purchased under and compensation expense associated with the 2012 Plan for the years reported are as follows: Years Ended June 30, 2020 2019 2018 Shares purchased under the plans 0.3 0.2 0.1 Plan compensation expense $ 1.7 $ 1.0 $ 0.1
Employee Stock Purchase Plan [Member]
Schedule of Fair Value of Stock Option Grant Weighted-Average Assumptions	The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black‑Scholes option-pricing model using the following weighted-average assumptions: 2020 2019 2018 Risk-free interest rate 1.8% 2.1% 2.1% Expected dividend yield 0% 0% 0% Expected life (in years) 0.5 0.5 0.5 Expected volatility 99% 55% 45%

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Schedule of Income Tax Benefit	Income tax benefit consists of the following: Year ended June 30, 2020 2019 2018 Current: Federal $ 26.6 $ (24.2 ) $ 7.7 State 4.9 (0.1 ) 2.2 Foreign 0.5 0.2 — Total current 32.0 (24.1 ) 9.9 Deferred: Federal (51.5 ) 17.8 (22.7 ) State (4.1 ) 1.7 0.7 Foreign (3.6 ) 0.4 (1.4 ) Change in valuation allowance 3.5 (0.2 ) 0.5 Total deferred (55.7 ) 19.7 (22.9 ) Total income tax benefit $ (23.7 ) $ (4.4 ) $ (13.0 )
Schedule of Income (Loss) Before Income Taxes	Income (loss) before income taxes consists of the following: Year ended June 30, 2020 2019 2018 United States $ (240.9 ) $ (0.6 ) $ 122.3 Foreign 17.6 0.6 (2.2 ) Total $ (223.3 ) $ — $ 120.1
Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported in Consolidated Statements of Operations	The differences between income taxes at the statutory federal income tax rate and income taxes reported in the consolidated statements of operations were as follows: Year ended June 30, 2020 2019 2018 Federal income tax expense at the statutory rate (46.9 ) 21.0 % — 21.0 % 33.7 28.1 % State income taxes, net of federal benefit (0.2 ) 0.1 % 2.0 6422.1 % 2.9 2.4 % Research and development credits, net of the federal tax on state credits (2.8 ) 1.3 % (3.7 ) -11880.9 % (2.1 ) -1.7 % Uncertain tax positions, net of federal benefit 1.9 -0.9 % 2.9 9312.1 % 2.5 2.1 % Uncertain tax benefits statute expired, net of federal benefit (0.4 ) 0.2 % (7.1 ) -22798.5 % — 0.0 % Incentive stock option and employee stock purchase plan expense (0.2 ) 0.1 % (3.1 ) -9954.3 % (1.7 ) -1.4 % Foreign rate differential 0.7 -0.3 % 0.8 2568.8 % (0.8 ) -0.7 % Change in valuation allowance 3.5 -1.7 % (0.2 ) -642.2 % 0.6 0.5 % Tax Cut and Jobs Act impact — 0.0 % — 0.0 % (32.0 ) -26.6 % Fair value adjustments related to acquisition contingent consideration — 0.0 % 0.8 2568.8 % (17.0 ) -14.2 % Non-deductible contingent purchase price and transaction costs (0.3 ) 0.1 % — 0.0 % — 0.0 % Non-deductible meals and entertainment 1.8 -0.8 % 1.3 4174.4 % 0.4 0.3 % Non-deductible officer compensation 1.6 -0.7 % 0.6 1926.6 % — 0.0 % Asset impairment 12.6 -5.6 % — 0.0 % — 0.0 % Expired tax attributes 4.2 -1.9 % — 0.0 % — 0.0 % Non-deductible legal settlement — 0.0 % 1.9 6101.0 % — 0.0 % Foreign disregarded election — 0.0 % 6.4 20550.8 % — 0.0 % Changes in revenue recognition/method — 0.0 % (7.3 ) -23440.8 % — 0.0 % Other, net 0.8 -0.3 % 0.3 963.4 % 0.5 0.5 % (23.7 ) 10.6 % (4.4 ) -14107.7 % (13.0 ) -10.7 %
Schedule of Components of Deferred Tax Assets and Liabilities	The significant components of the Company’s deferred tax assets and liabilities were comprised of the following: Year ended June 30, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 73.1 $ 85.7 Property, plant and equipment 37.2 — Accrued vacation 1.5 1.2 AR allowance 1.2 3.3 Stock compensation expense 13.8 16.0 Research and development credits 27.6 25.4 Lease right-of-use asset 16.3 — Uncertain state tax positions 1.6 1.3 Other, net 9.6 9.0 Total gross deferred tax assets 181.9 141.9 Less valuation allowance (42.4 ) (38.9 ) Total deferred tax assets 139.5 103.0 Deferred tax liabilities: Intangible assets 150.3 175.4 Lease liability 15.8 — Property, plant and equipment — 2.5 Deferred revenue — 7.7 Total deferred tax liabilities 166.1 185.6 Net deferred tax liability $ (26.6 ) $ (82.6 )
Summary of Net Operating Loss and Research Credit Carryforwards (Tax Effected)	At June 30, 2020, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated. Subject to Expires Carryforwards Amount sections 382, beginning in year Through Federal net operating loss $ 52.5 Yes 2031 2038 Utah net operating loss 2.7 No 2021 2033 California net operating loss 3.5 No 2027 2040 Other state net operating loss 6.9 Yes 2027 2040 Foreign net operating losses (various jurisdictions) 7.6 No Various Various Federal research credit 11.2 Yes 2027 2040 Utah research credit 11.6 No 2030 2034 California research credit 4.7 No 2027 2040 Texas research credit 0.1 No 2039 2040
Schedule of Reconciliation of Beginning and Ending Unrecognized Tax Benefits	Year ended June 30, 2020 2019 2018 Unrecognized tax benefits at the beginning of year $ 21.7 $ 24.9 $ 25.2 Gross increases - current year tax positions 1.6 2.2 0.6 Gross increases - prior year tax positions 0.7 0.5 2.4 Gross increases - acquisitions — 2.3 — Gross decreases - prior year tax positions — (0.1 ) (3.3 ) Gross decreases - settlements — (2.7 ) — Gross decreases - statute lapse (0.5 ) (5.4 ) — Unrecognized tax benefits at end of year $ 23.5 $ 21.7 $ 24.9 Interest and penalties in year-end balance $ 1.4 $ 0.8 $ 1.5

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2020
Lessee Disclosure [Abstract]
Maturities of Operating Lease Liabilities	As of June 30, 2020, the maturities of the Company’s operating lease liabilities were as follows: Fiscal year ending: 2021 $ 15.9 2022 14.8 2023 13.6 2024 13.2 2025 10.9 Thereafter 9.6 Total future lease payments 78.0 Less: amounts representing interest (7.6 ) Present value of future lease payments 70.4 Less: current maturities of operating lease liabilities 13.5 Noncurrent operating lease liabilities $ 56.9
Schedule of Future Minimum Lease Payments Required under Noncancelable Operating Leases	Future minimum lease payments required under noncancelable operating leases that have initial or remaining noncancelable lease term in excess of one year at June 30, 2019 are as follows: Fiscal year ending: 2020 $ 15.1 2021 14.1 2022 13.1 2023 12.2 2024 11.9 Thereafter 19.1 $ 85.5

Employee Deferred Savings Plan

Employee Deferred Savings Plan (Tables)	12 Months Ended
	Jun. 30, 2020
Postemployment Benefits [Abstract]
Company Recorded Contributions To Plan	The Company’s recorded contributions to the plan for the fiscal years reported are as follows: Years Ended June 30, 2020 2019 2018 Deferred savings plan contributions $ 7.1 $ 8.3 $ 7.2

Segment and Related Informati_2

Segment and Related Information (Tables)	12 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense	The Company evaluates segment performance based on income (loss) before interest income and other income and expense. Diagnostics Other Total Year ended June 30, 2020: Revenues $ 593.5 $ 45.1 $ 638.6 Depreciation and amortization 68.2 3.8 72.0 Segment operating loss (82.4 ) (149.3 ) (231.7 ) Year ended June 30, 2019: Revenues $ 789.4 $ 61.7 $ 851.1 Depreciation and amortization 67.7 5.3 73.0 Segment operating income (loss) 133.3 (125.7 ) 7.6 Year ended June 30, 2018: Revenues $ 690.4 $ 53.3 $ 743.7 Depreciation and amortization 49.2 5.2 54.4 Segment operating income (loss) 142.6 (20.7 ) 121.9 Years Ended June 30, 2020 2019 2018 Total operating income (loss) for reportable segments $ (231.7 ) $ 7.6 $ 121.9 Unallocated amounts: Interest income 3.0 3.2 1.8 Interest expense (10.8 ) (12.0 ) (3.2 ) Other 16.2 1.2 (0.4 ) Income (loss) from operations before income taxes (223.3 ) — 120.1 Income tax benefit (23.7 ) (4.4 ) (13.0 ) Net income (loss) (199.6 ) 4.4 133.1 Net loss attributable to non-controlling interest (0.1 ) (0.2 ) (0.2 ) Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (199.5 ) $ 4.6 $ 133.3
Schedule Of Comparison of Balance Sheet Assets by Operating Segment	The following table sets forth a comparison of balance sheet assets by operating segment: June 30, 2020 2019 Net equipment, leasehold improvements and property: Diagnostics $ 23.9 $ 25.7 Other 13.1 31.6 Total $ 37.0 $ 57.3 Total Assets: Diagnostics $ 1,002.8 $ 1,215.6 Other 147.0 155.3 Total $ 1,149.8 $ 1,370.9
Summary of Assets by Geographical Region	The following table reconciles assets by geographical region: June 30, 2020 2019 Net equipment, leasehold improvements and property: United States $ 35.4 $ 36.0 Rest of world 1.6 21.3 Total $ 37.0 $ 57.3 Total Assets: United States $ 1,097.2 $ 1,265.8 Rest of world 52.6 105.1 Total $ 1,149.8 $ 1,370.9
Reconciliation of Assets by Operating Segment and Geographic Region to Total Assets	The following table reconciles assets by operating segment and geographic region to total assets: June 30, 2020 2019 Total assets by segment and geographical region $ 1,149.8 $ 1,370.9 Cash, cash equivalents, and marketable investment securities (1) 254.8 191.8 Total $ 1,404.6 $ 1,562.7 (1) The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments.

Business Acquisitions (Tables)

Business Acquisitions (Tables)	12 Months Ended
	Jun. 30, 2020
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the years ended June 30, 2020 and 2019 are as follows: Diagnostic Other Total Years Ended June 30, Years Ended June 30, Years Ended June 30, 2020 2019 2020 2019 2020 2019 Beginning balance $ 351.6 $ 252.8 $ 65.6 $ 65.8 $ 417.2 $ 318.6 Acquisitions (see note 19) — 94.9 — — — 94.9 Adjustments to acquisitions (see note 19) — 4.4 — — — 4.4 Goodwill deconsolidated on sale of Clinic — — (7.3 ) — (7.3 ) — Goodwill impairment charge (80.7 ) — (1.3 ) — (82.0 ) — Translation adjustments (0.2 ) (0.5 ) (0.1 ) (0.2 ) (0.3 ) (0.7 ) Ending balance $ 270.7 $ 351.6 $ 56.9 $ 65.6 $ 327.6 $ 417.2
Counsyl Inc [Member]
Allocation of Consideration Transferred	The allocation of the consideration transferred was finalized within the measurement period Estimated Fair Value Current assets $ 42.5 Intangible assets 290.0 Equipment 18.2 Other assets 0.1 Goodwill 99.3 Current liabilities (19.6 ) Long term liabilities (0.1 ) Deferred tax liability (9.2 ) Total fair value purchase price $ 421.2 Less: Cash acquired (15.3 ) Total consideration transferred $ 405.9
Changes in Carrying Amount of Goodwill	Changes in goodwill since the initial purchase are shown below: Carrying amount Balance September 30, 2018 $ 94.9 Fair value adjustment to equipment 0.7 Intangible adjustment 2.9 Working capital adjustment (1.1 ) Change in deferred tax liability 1.9 Ending balance June 30, 2020 $ 99.3
Pro Forma Results of Acquisitions	Accordingly, these unaudited pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operation of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations and are not necessarily indicative of results that might have been achieved had the acquisition been consummated as of July 1, 2017. Year Ended Year Ended June 30, June 30, 2019 2018 Revenue $ 861.3 $ 881.8 Income from operations 17.9 74.3 Net income 13.8 73.0 Net income per share, basic $ 0.19 $ 1.01 Net income per share, diluted $ 0.18 $ 0.98

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Jun. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	Years Ended June 30, 2020 2019 2018 Cash paid for income taxes $ 1.0 $ 6.5 $ 11.7 Cash paid for interest 9.5 11.6 3.0 Non-cash investing and financing activities: Fair value adjustment on marketable investment securities recorded to stockholders' equity 0.7 1.2 (0.4 ) Establishment of operation lease right-of-use assets and lease liabilities Operating lease right-of-use assets $ 74.5 — — Operating lease liabilities (78.8 ) — — Accrued liabilities and other long-term liabilities 4.3 — —

Supplementary Quarterly Finan_2

Supplementary Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2020
Quarterly Financial Data [Abstract]
Schedule of Quarterly Financial Data	In millions, except per share amounts Quarters Ended Jun 30, Mar 31, Dec 31, Sep 30, Consolidated Statement of Operations Data: 2019 2019 2018 2018 Molecular diagnostic testing $ 196.9 $ 200.5 $ 203.0 $ 189.0 Pharmaceutical and clinical services 18.5 16.1 13.8 13.3 Total revenue 215.4 216.6 216.8 202.3 Costs and expenses: Cost of molecular diagnostic testing 41.6 40.3 44.0 42.3 Cost of pharmaceutical and clinical services 9.0 8.3 8.1 7.4 Research and development expense 20.9 21.5 22.4 21.1 Change in contingent consideration (0.3 ) — 1.0 0.4 Selling, general and administrative expense 149.8 140.6 135.2 129.9 Total costs and expenses 221.0 210.7 210.7 201.1 Operating income (loss) (5.6 ) 5.9 6.1 1.2 Other income (expense): Interest income 0.9 0.7 0.9 0.7 Interest expense (3.2 ) (3.2 ) (3.4 ) (2.2 ) Other 0.2 (0.1 ) — 1.1 Total other income (expense) (2.1 ) (2.6 ) (2.5 ) (0.4 ) Income (loss) before income taxes (7.7 ) 3.3 3.6 0.8 Income tax provision (benefit) (3.4 ) (3.6 ) 1.0 1.6 Net income (loss) (4.3 ) 6.9 2.6 (0.8 ) Net loss attributable to non-controlling interest (0.1 ) — — (0.1 ) Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (4.2 ) $ 6.9 $ 2.6 $ (0.7 ) Earnings (loss) per share: Basic $ (0.06 ) $ 0.09 $ 0.04 $ (0.01 ) Diluted $ (0.06 ) $ 0.09 $ 0.03 $ (0.01 ) Weighted average shares outstanding: Basic 73.4 73.3 74.2 73.0 Diluted 74.8 74.9 76.5 73.0

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2020USD ($)PayorCustomer$ / shares	Jun. 30, 2019USD ($)Customer	Jun. 30, 2018USD ($)	Jul. 01, 2019USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of major customers comprising more than ten10 % of revenues | Customer		0	0
Other-than-temporary impairments		$ 0	$ 0	$ 0
CARES act of 2020, medicare payment amount		$ 29,700,000
Revenue, practical expedient, remaining performance obligation, description		In accordance with ASU 2014-09, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, periodically the Company enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical and clinical services that may have terms longer than one year and include multiple performance obligations.
Revenue, practical expedient, remaining performance obligation		true
Revenue, practical expedient, initial application and transition, nondisclosure of transaction price allocation to remaining performance obligation		true
Revenue, remaining performance obligation	$ 2,700,000	$ 2,700,000
Revenue decrease performance obligation	400,000	$ 9,900,000
Change in earnings (loss) per share | $ / shares		$ (0.10)
Accrued liabilities	75,900,000	$ 75,900,000	$ 78,900,000
Capitalized costs incurred to obtain or fulfill contract	0	$ 0
Revenue practical expedient, incremental cost of obtaining contract		true
Revenue, performance obligation, description of payment terms		This practical expedient has been elected because the Company collects very little cash from customers under payment terms and vast majority of payments terms have a payback period of less than one year.
CARES act of 2020, provider fund amount		$ 14,600,000
Operating lease liability	70,400,000	70,400,000
Operating lease right-of-use assets	66,000,000	66,000,000
Current maturities of operating lease liabilities	13,500,000	13,500,000
Noncurrent operating lease liabilities	56,900,000	56,900,000
ASU 2016-02 [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Operating lease liability	78,800,000	78,800,000			$ 78,800,000
Operating lease right-of-use assets	$ 74,500,000	$ 74,500,000			74,500,000
Current maturities of operating lease liabilities					65,700,000
Noncurrent operating lease liabilities					$ 74,500,000
Correction of Error in Current Period [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Change in earnings (loss) per share | $ / shares	$ (0.05)	$ (0.05)
Minimum [Member] | Equipment [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives, in years		5 years
Minimum [Member] | Leasehold Improvements [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives, in years		3 years
Maximum [Member] | Equipment [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives, in years		7 years
Maximum [Member] | Leasehold Improvements [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives, in years		7 years
Medicare [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of payor that receives greater than 10% of its revenues | Payor		1
Percentage of revenues from Medicare		15.00%	14.00%	17.00%
Accrued liabilities	$ 4,700,000	$ 4,700,000
Medicare [Member] | Minimum [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of revenues from Medicare		10.00%

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies - Reconciliation of Deferred Revenue Balances (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Revenue From Contract With Customer [Abstract]
Deferred revenue - beginning balance	$ 2.2	$ 2.6
Revenue recognized	(7.2)	(7.9)
Prepayments	37.8	7.5
Deferred revenue - ending balance	$ 32.8	$ 2.2

Organization and Summary of S_6

Organization and Summary of Significant Accounting Policies - Schedule of Company's Revenue by Type (Detail) - USD ($) $ in Millions	3 Months Ended									12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Disaggregation Of Revenue [Line Items]
Total revenue	$ 93.2	$ 164	$ 195.1		$ 186.3	$ 215.4	$ 216.6	$ 216.8	$ 202.3	$ 638.6	$ 851.1	$ 743.7
Molecular Diagnostic - Hereditary Cancer Testing [Member]
Disaggregation Of Revenue [Line Items]
Total revenue										347.4	479.7	471.4
Molecular Diagnostic - GeneSight [Member]
Disaggregation Of Revenue [Line Items]
Total revenue										74.1	112.6	124.9
Molecular Diagnostic - Prenatal [Member]
Disaggregation Of Revenue [Line Items]
Total revenue										76.7	104.9
Molecular Diagnostic- Vectra [Member]
Disaggregation Of Revenue [Line Items]
Total revenue										39.1	48.3	55.2
Molecular Diagnostic - Prolaris [Member]
Disaggregation Of Revenue [Line Items]
Total revenue										24.7	25.5	21.5
Molecular Diagnostic - EndoPredict [Member]
Disaggregation Of Revenue [Line Items]
Total revenue										10.5	10.4	8.8
Molecular Diagnostic - Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue										14.4	8	8.6
Molecular Diagnostic Testing [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	83.3	150.5	181.1		172	196.9	200.5	203	189	586.9	789.4	690.4
Pharmaceutical and Clinical Services [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 9.9	$ 13.5	$ 14		$ 14.3	$ 18.5	$ 16.1	$ 13.8	$ 13.3	$ 51.7	$ 61.7	$ 53.3
[1]	An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.

Organization and Summary of S_7

Organization and Summary of Significant Accounting Policies - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Detail) - shares	3 Months Ended									12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Equity [Abstract]
Weighted-average shares outstanding used to compute basic EPS	74.6	74.5	74.4		73.7	73.4	73.3	74.2	73	74,300,000	73,500,000	69,400,000
Effect of dilutive stock options											2,500,000	2,600,000
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS	74.6	74.5	74.4		73.7	74.8	74.9	76.5	73	74,300,000	76,000,000	72,000,000
[1]	An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.

Organization and Summary of S_8

Organization and Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation (Detail) - shares shares in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Equity [Abstract]
Anti-dilutive options and RSUs excluded from EPS computation	5.5	0.8

Organization and Summary of S_9

Organization and Summary of Significant Accounting Policies - Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent [Abstract]
Ending balance	$ (7.2)
Period translation adjustments	(0.6)	$ (3.1)	$ 1.6
Reclassification upon deconsolidation of subsidiary	1.3
Ending balance	$ (6.5)	$ (7.2)

Marketable Investment Securit_3

Marketable Investment Securities - Schedule of Fair Value Debt Securities Classified as Available-for-Sale Securities by Major Security Type and Class of Security (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	$ 163.7	$ 93.2
Available-for-sale, Amortized cost	253.5	191.2
Gross unrealized holding gains	1.3	0.6
Available-for-sale, Estimated fair value	254.8	191.8
Amortized cost	253.5	191.2
Estimated fair value	254.8	191.8
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	132.8	68.7
Cash and cash equivalents, Estimated fair value	132.8	68.7
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	30.9	24.5
Cash and cash equivalents, Estimated fair value	30.9	24.5
Total Cash and Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	163.7	93.2
Cash and cash equivalents, Estimated fair value	163.7	93.2
Corporate Bonds and Notes [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	50.1	64
Gross unrealized holding gains	0.8	0.6
Available-for-sale, Estimated fair value	50.9	64.6
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	17.8	15.3
Gross unrealized holding gains	0.2
Available-for-sale, Estimated fair value	18	15.3
Federal Agency Issues [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	5.5	9
Gross unrealized holding gains	0.1
Available-for-sale, Estimated fair value	5.6	9
US Government Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale, Amortized cost	16.4	9.7
Gross unrealized holding gains	0.2
Available-for-sale, Estimated fair value	$ 16.6	$ 9.7

Marketable Investment Securit_4

Marketable Investment Securities - Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	$ 163.7	$ 93.2
Due within one year, Amortized cost	53.7
Due after one year through five years, Amortized cost	36.1
Total, Amortized cost	253.5	191.2
Due within one year, Estimated fair value	54.1
Due after one year through five years, Estimated fair value	37
Total, Estimated fair value	254.8	191.8
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	132.8	68.7
Cash equivalents, Estimated fair value	132.8	68.7
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Amortized cost	30.9	24.5
Cash equivalents, Estimated fair value	$ 30.9	$ 24.5

Marketable Investment Securit_5

Marketable Investment Securities - Additional Information (Detail) - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Investments Debt And Equity Securities [Abstract]
Gross unrealized loss position debt securities classified as available for sale	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Impairment of goodwill			$ 82
Clinic Asset Group [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Impairment of goodwill		$ 1.3
Level 3 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Estimated fair value of long-term debt			$ 225.5	$ 192.7
Level 3 [Member] | Clinic Asset Group [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Impairment of goodwill		$ 1.3
Level 3 [Member] | Crescendo Bioscience, inc. [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Impairment of goodwill	$ 80.7

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Assets and Liabilities (Detail) - USD ($) $ in Millions		Jun. 30, 2020	Jun. 30, 2019
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		$ 115.2	$ 104.5
Money Market Funds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	[1]	30.9	17.2
Corporate Bonds and Notes [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		50.9	66.9
Municipal Bonds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		18	15.4
Federal Agency Issues [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		5.6	9
US Government Securities [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		16.6	9.8
Level 1 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		30.9	19.7
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets	[1]	30.9	17.2
Level 1 [Member] | Corporate Bonds and Notes [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets			2.5
Level 2 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		91.1	98.6
Level 2 [Member] | Corporate Bonds and Notes [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		50.9	64.4
Level 2 [Member] | Municipal Bonds [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		18	15.4
Level 2 [Member] | Federal Agency Issues [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		5.6	9
Level 2 [Member] | US Government Securities [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets		16.6	9.8
Level 3 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial assets and liability		(6.8)	(13.8)
Contingent Consideration [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial liability		(6.8)	(13.8)
Contingent Consideration [Member] | Level 3 [Member]
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]
Total fair value of financial liability		$ (6.8)	$ (13.8)
[1]	Money market funds are primarily comprised of exchange traded funds and accrued interest.

Fair Value Measurements - Chang

Fair Value Measurements - Change in Fair Value of Contingent Consideration (Detail) $ in Millions	12 Months Ended
	Jun. 30, 2020USD ($)
Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Abstract]
Balance June 30, 2019	$ 13.8
Payment of contingent consideration	(3.9)
Change in fair value recognized in the statement of operations	(2.8)
Translation adjustments recognized in other comprehensive income	(0.3)
Balance June 30, 2020	$ 6.8

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Land		$ 2.3
Buildings and improvements		18.8
Leasehold improvements	$ 31.8	31
Equipment	112.1	117.1
Gross property, plant and equipment	143.9	169.2
Less accumulated depreciation	(106.9)	(111.9)
Property, plant and equipment, net	$ 37	$ 57.3

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Detail) $ in Millions	Mar. 31, 2020USD ($)
Clinic Asset Group [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 19.5

Property, Plant and Equipment_5

Property, Plant and Equipment, Net - Schedule of Depreciation Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Depreciation expense	$ 11	$ 13.7	$ 17.1

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Changes in Carrying Amount of Good (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Goodwill And Intangible Assets [Line Items]
Beginning balance	$ 417.2	$ 318.6
Acquisitions		94.9
Adjustments to acquisitions		4.4
Goodwill deconsolidated on sale of Clinic	(7.3)
Goodwill impairment charge	(82)
Translation adjustments	(0.3)	(0.7)
Ending balance	327.6	417.2
Diagnostic [Member]
Goodwill And Intangible Assets [Line Items]
Beginning balance	351.6	252.8
Acquisitions		94.9
Adjustments to acquisitions		4.4
Goodwill impairment charge	(80.7)
Translation adjustments	(0.2)	(0.5)
Ending balance	270.7	351.6
Other [Member]
Goodwill And Intangible Assets [Line Items]
Beginning balance	65.6	65.8
Goodwill deconsolidated on sale of Clinic	(7.3)
Goodwill impairment charge	(1.3)
Translation adjustments	(0.1)	(0.2)
Ending balance	$ 56.9	$ 65.6

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Goodwill And Intangible Assets [Line Items]
Goodwill impairment charge			$ 82,000,000
Intangible assets impairment charge	$ 17,700,000
Impairment of long-lived assets			0	$ 0	$ 0
Estimated amortization expenses of intangible assets for 2021			51,900,000
Estimated amortization expenses of intangible assets for 2022			45,000,000
Estimated amortization expenses of intangible assets for 2023			43,600,000
Estimated amortization expenses of intangible assets for 2024			43,400,000
Estimated amortization expenses of intangible assets for 2025			43,400,000
Estimated amortization expenses of intangible assets after 2024			$ 373,200,000
Developed Technology and Database [Member] | Minimum [Member]
Goodwill And Intangible Assets [Line Items]
Estimated useful life			3 years
Developed Technology and Database [Member] | Maximum [Member]
Goodwill And Intangible Assets [Line Items]
Estimated useful life			16 years
Trademarks [Member]
Goodwill And Intangible Assets [Line Items]
Estimated useful life			8 years
Weighted average remaining amortization period			11 years
Customer Relationships [Member]
Goodwill And Intangible Assets [Line Items]
Estimated useful life			1 year
Weighted average remaining amortization period			11 years
Purchased Licenses and Technologies [Member]
Goodwill And Intangible Assets [Line Items]
Weighted average remaining amortization period			11 years
Clinic Asset Group [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill impairment charge		$ 1,300,000
Crescendo Bioscience, Inc. [Member]
Goodwill And Intangible Assets [Line Items]
Goodwill impairment charge	$ 80,700,000

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Summarized Amounts Reported as Intangible Assets (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	$ 823.2	$ 823.3
Gross Carrying Amount, total intangible assets	828	846.3
Accumulated Amortization	(222.7)	(161.6)
Net, amortized intangible assets	600.5	661.7
Net, total intangible assets	605.3	684.7
Net, non-amortizable intangible assets	4.8	23
In-Process Research and Development [Member]
Intangible Assets [Line Items]
Net, non-amortizable intangible assets	4.8	23
Purchased Licenses and Technologies [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	815.6	815.7
Accumulated Amortization	(217.1)	(156.6)
Net, amortized intangible assets	598.5	659.1
Customer Relationships [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	4.6	4.6
Accumulated Amortization	(4.2)	(3.8)
Net, amortized intangible assets	0.4	0.8
Trademarks [Member]
Intangible Assets [Line Items]
Gross Carrying Amount, amortized intangible assets	3	3
Accumulated Amortization	(1.4)	(1.2)
Net, amortized intangible assets	$ 1.6	$ 1.8

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization on Intangible Assets (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 61	$ 59.3	$ 37.3

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Payables And Accruals [Abstract]
Employee compensation and benefits	$ 47.4	$ 48.8
Accrued taxes payable	6.1	3
Qui tam settlement		9.1
Other	22.4	18
Total accrued liabilities	$ 75.9	$ 78.9

Long Term Debt - Additional Inf

Long Term Debt - Additional Information (Detail) - USD ($)	May 01, 2020	Jul. 31, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Dec. 23, 2016
Debt Instrument [Line Items]
Aggregate principal amount of loan			$ 226,700,000	$ 235,000,000
Long term debt, net			224,400,000	233,500,000
Principal repayment			$ 8,600,000	115,000,000	$ 143,000,000
Second Amendment to Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate on variable basis	0.50%		2.00%
Debt instrument, interest rate during the period			4.50%
Second Amendment to Credit Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate on variable basis			0.25%
Second Amendment to Credit Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate on variable basis			0.45%
Second Amendment to Credit Facility [Member] | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, interest rate on variable basis	3.50%
Debt instrument, interest rate during the period	1.00%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Principal repayment			$ 8,600,000	$ 115,000,000	$ 143,000,000
Revolving Credit Facility [Member] | Amendment to Credit Agreement [Member]
Debt Instrument [Line Items]
Aggregate principal amount of loan		$ 300,000,000
Upfront fees		1,800,000
Debt issuance costs		300,000
Long term debt, net		224,400,000
Scheduled principal payments prior to maturity date		0
Revolving Credit Facility [Member] | Second Amendment to Credit Facility [Member]
Debt Instrument [Line Items]
Upfront fees		1,000,000
Debt issuance costs		$ 1,000,000
Revolving Credit Facility [Member] | Counsyl Inc [Member] | Amendment to Credit Agreement [Member]
Debt Instrument [Line Items]
Loan agreement, maturity date		Jul. 31, 2023
Loans maximum borrowing capacity		$ 350,000,000				$ 300,000,000
Revolving Credit Facility [Member] | Counsyl Inc [Member] | Second Amendment to Credit Facility [Member]
Debt Instrument [Line Items]
Amendment period	Amendment Period from March 31, 2020 through June 30, 2021
Amendment period, Start Date	Mar. 31, 2020
Amendment period, End Date	Jun. 30, 2021

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-Term Debt (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Long-term Debt, Unclassified [Abstract]
Long-term debt	$ 226.7	$ 235
Long-term debt discount	(2.3)	(1.5)
Net long-term debt	$ 224.4	$ 233.5

Other Long Term Liabilities - S

Other Long Term Liabilities - Summary of Other Long Term Liabilities (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Other Liabilities Disclosure [Abstract]
Pension obligation		$ 6.8
Other	$ 4.3	1
Total other long-term liabilities	$ 4.3	$ 7.8

Other Long Term Liabilities - A

Other Long Term Liabilities - Additional Information (Detail) $ in Millions	Jun. 30, 2019USD ($)plan
Other Liabilities Disclosure [Abstract]
Number of defined benefit pension plans | plan	2
Fair value of plan assets	$ 0.1
Net pension liability	$ 6.8

Preferred and Common Stockhol_3

Preferred and Common Stockholder's Equity - Additional Information (Detail) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Class Of Stock Disclosures [Abstract]
Preferred stock, shares authorized		5,000,000
Preferred stock, par value		$ 0.01
Preferred stock, shares outstanding	0	0	0
Common stock, shares authorized		150,000,000
Common stock, par value		$ 0.01
Common stock, shares issued	73,500,000	74,700,000	70,600,000	68,400,000
Common stock, shares outstanding	73,500,000	74,700,000	70,600,000	68,400,000
Share repurchase program, authorized amount					$ 200,000,000
Share repurchase program, remaining authorized repurchase amount		$ 110,700,000
Payments for repurchase of company stock	$ 50,000,000

Preferred and Common Stockhol_4

Preferred and Common Stockholder's Equity - Summary of Common Shares Issued and Outstanding (Detail) - shares shares in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Equity [Abstract]
Common stock issued, Beginning balance	73.5	70.6	68.4
Common stock outstanding, Beginning balance	73.5	70.6	68.4
Common stock issued upon exercise of options and employee stock plans	1.2	4.5	2.2
Repurchase and retirement of common stock		(1.6)
Common stock issued, Ending balance	74.7	73.5	70.6
Common stock outstanding, Ending balance	74.7	73.5	70.6

Preferred and Common Stockhol_5

Preferred and Common Stockholder's Equity - Schedule of Stock Repurchases (Detail) shares in Millions, $ in Millions	12 Months Ended
	Jun. 30, 2019USD ($)shares
Stockholders Equity [Line Items]
Shares purchased and retired | shares	1.6
Common stock and additional paid-in-capital reductions | $	$ 16.9
Charges to retained earnings | $	$ 33.1
Common Stock [Member]
Stockholders Equity [Line Items]
Shares purchased and retired | shares	1.6

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Dec. 05, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, description		Options and RSUs granted to the Company’s non-employee directors vest in full upon completion of one year of service on the Board following the date of the grant
Options granted, Number of shares		0	0	0
Total unrecognized share-based compensation cost related to stock options		$ 0
Stock options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service period of share-based compensation vested, years		4 years
Stock options [Member] | Share-based compensation granted after December 5, 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expire from date of grant, years		8 years
Stock options [Member] | Share-based compensation granted prior to December 5, 2012 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expire from date of grant, years		10 years
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service period of share-based compensation vested, years	4 years
RSUs granted, Weighted average grant date fair value		$ 27.96	$ 46.62	$ 32.67
Fair value of restricted stock units, vested		$ 32.4	$ 27.6	$ 20.4
Total unrecognized share-based compensation cost related to RSUs		$ 38.2
Total unrecognized share-based compensation cost, weighted-average period, years		2 years 1 month 6 days
Unrecognized share-based compensation cost		$ 38.2
Restricted Stock Units (RSUs) [Member] | Non Employee Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service period of share-based compensation vested, years		1 year
The 2017 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares approved		2,200,000
2003 Plan [Member] | Stock options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future grant		100,000
The 2010 Plan [Member] | Options and Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future grant		4,500,000
2012 Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares approved					2,000,000
Shares issued under the Plan		1,700,000
Unrecognized share-based compensation cost		$ 0.7

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) - $ / shares	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding at beginning of year, Number of shares	5,500,000
Options granted, Number of shares	0	0	0
Options exercised, Number of shares	(400,000)
Options canceled or expired, Number of shares	(300,000)
Options outstanding at end of year, Number of shares	4,800,000	5,500,000
Options exercisable at end of year, Number of shares	4,800,000
Options vested and expected to vest, Number of shares	4,800,000
Options outstanding at beginning of year, Weighted average exercise price	$ 24.45
Options exercised, Weighted average exercise price	22.56
Options canceled or expired, Weighted average exercise price	26.69
Options outstanding at end of year, Weighted average exercise price	24.47	$ 24.45
Options exercisable at end of year, Weighted average exercise price	24.47
Options vested and expected to vest, Weighted average exercise price	$ 24.47

Share-Based Compensation - Sc_2

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding and Exercisable (Detail) shares in Millions	12 Months Ended
	Jun. 30, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number outstanding at June 30,2020, Options outstanding | shares	4.8
Weighted average remaining contractual life (years), Options outstanding	1 year 5 months 26 days
Weighted average exercise price, Options exercisable	$ 24.47
$ 14.88 - 21.29 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Range of exercise prices, minimum	14.88
Range of exercise prices, maximum	$ 21.29
Number outstanding at June 30,2020, Options outstanding | shares	1.3
Weighted average remaining contractual life (years), Options outstanding	1 year 14 days
Weighted average exercise price, Options exercisable	$ 19.09
$ 21.66 - 25.39 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Range of exercise prices, minimum	21.66
Range of exercise prices, maximum	$ 25.39
Number outstanding at June 30,2020, Options outstanding | shares	0.5
Weighted average remaining contractual life (years), Options outstanding	1 year 3 months 29 days
Weighted average exercise price, Options exercisable	$ 24.04
$ 26.49 - 26.49 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Range of exercise prices, minimum	26.49
Range of exercise prices, maximum	$ 26.49
Number outstanding at June 30,2020, Options outstanding | shares	1.5
Weighted average remaining contractual life (years), Options outstanding	1 year 2 months 19 days
Weighted average exercise price, Options exercisable	$ 26.49
$ 27.07 - 36.55 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Range of exercise prices, minimum	27.07
Range of exercise prices, maximum	$ 36.55
Number outstanding at June 30,2020, Options outstanding | shares	1.5
Weighted average remaining contractual life (years), Options outstanding	2 years 2 months 12 days
Weighted average exercise price, Options exercisable	$ 27.18

Share-Based Compensation - Sc_3

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding (Detail) - Restricted Stock Units (RSUs) [Member] - $ / shares shares in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
RSUs outstanding at beginning of year, Number of shares	2.4
RSUs granted, Number of shares	1.3
RSUs released, Number of shares	(0.9)
RSUs canceled, Number of shares	(0.5)
RSUs outstanding at end of year, Number of shares	2.3	2.4
RSUs outstanding at beginning of year, Weighted average grant date fair value	$ 37.70
RSUs granted, Weighted average grant date fair value	27.96	$ 46.62	$ 32.67
RSUs released, Weighted average grant date fair value	35.63
RSUs canceled, Weighted average grant date fair value	37.80
RSUs outstanding at end of year, Weighted average grant date fair value	$ 32.50	$ 37.70

Share-Based Compensation - Sc_4

Share-Based Compensation - Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 25.2	$ 33.5	$ 27.1
Molecular Diagnostic Testing Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	1.2	0.8	0.7
Pharmaceutical and Clinical Services Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	0.3	0.2	0.2
Research and Development Expense [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	5	5.4	4.3
Selling, General, and Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 18.7	$ 27.1	$ 21.9

Share-Based Compensation - Sc_5

Share-Based Compensation - Schedule of Unrecognized Share-Based Compensation Cost (Detail) - Restricted Stock Units (RSUs) [Member] $ in Millions	Jun. 30, 2020USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share-based compensation cost	$ 38.2
Aggregate intrinsic value of RSUs outstanding	$ 25.9

Share-Based Compensation - Sc_6

Share-Based Compensation - Schedule of Intrinsic Value of Options Exercised (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Total intrinsic value of options exercised	$ 8.8	$ 0.4	$ 17

Share-Based Compensation - Sc_7

Share-Based Compensation - Schedule of Shares Purchased and Compensation Expenses (Detail) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares purchased under the plans	0.3	0.2	0.1
Plan compensation expense	$ 1.7	$ 1	$ 0.1

Share-Based Compensation - Sc_8

Share-Based Compensation - Schedule of Fair Value of Stock Option Grant with Weighted-Average Assumptions (Detail) - Employee Stock Purchase Plan [Member]	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	1.80%	2.10%	2.10%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life (in years)	6 months	6 months	6 months
Expected volatility	99.00%	55.00%	45.00%

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Benefit (Detail) - USD ($) $ in Millions	3 Months Ended									12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Current, Federal										$ 26.6	$ (24.2)	$ 7.7
Current, State										4.9	(0.1)	2.2
Current, Foreign										0.5	0.2
Total current										32	(24.1)	9.9
Deferred, Federal										(51.5)	17.8	(22.7)
Deferred, State										(4.1)	1.7	0.7
Deferred, Foreign										(3.6)	0.4	(1.4)
Change in valuation allowance										3.5	(0.2)	0.5
Total deferred										(55.7)	19.7	(22.9)
Income tax benefit	$ (3)	$ (15.9)	$ (3.1)		$ (1.7)	$ (3.4)	$ (3.6)	$ 1	$ 1.6	$ (23.7)	$ (4.4)	$ (13)
[1]	An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.

Income Taxes - Schedule of In_2

Income Taxes - Schedule of Income (Loss) Before Income Taxes (Detail) - USD ($) $ in Millions	3 Months Ended									12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income (loss) before income taxes, United States										$ (240.9)	$ (0.6)	$ 122.3
Income (loss) before income taxes, Foreign										17.6	$ 0.6	(2.2)
Income (loss) before income tax	$ (58.5)	$ (131.1)	$ (11.4)		$ (22.3)	$ (7.7)	$ 3.3	$ 3.6	$ 0.8	$ (223.3)		$ 120.1
[1]	An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.

Income Taxes - Schedule of Diff

Income Taxes - Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended									6 Months Ended		12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Federal income tax expense at the statutory rate										21.00%	35.00%	21.00%	21.00%	28.10%
State income taxes, net of federal benefit												0.10%	6422.10%	2.40%
Research and development credits, net of the federal tax on state credits												1.30%	(11880.90%)	(1.70%)
Uncertain tax positions, net of federal benefit												(0.90%)	9312.10%	2.10%
Uncertain tax benefits statute expired, net of federal benefit												0.20%	(22798.50%)	0.00%
Incentive stock option and employee stock purchase plan expense												0.10%	(9954.30%)	(1.40%)
Foreign rate differential												(0.30%)	2568.80%	(0.70%)
Change in valuation allowance												(1.70%)	(642.20%)	0.50%
Tax Cut and Jobs Act impact												0.00%	0.00%	(26.60%)
Fair value adjustments related to acquisition contingent consideration												(0.00%)	2568.80%	(14.20%)
Non-deductible contingent purchase price and transaction costs												0.10%	0.00%	0.00%
Non-deductible meals and entertainment												(0.80%)	4174.40%	0.30%
Non-deductible officer compensation												(0.70%)	1926.60%	0.00%
Asset impairment												(5.60%)	0.00%	0.00%
Expired tax attributes												(1.90%)	0.00%	0.00%
Non-deductible legal settlement												0.00%	6101.00%	0.00%
Foreign disregarded election												0.00%	20550.80%	0.00%
Changes in revenue recognition/method												0.00%	(23440.80%)	0.00%
Other, net												(0.30%)	963.40%	0.50%
Effective income tax rate												10.60%	(14107.70%)	(10.70%)
Federal income tax expense at the statutory rate												$ (46.9)		$ 33.7
State income taxes, net of federal benefit												(0.2)	$ 2	2.9
Research and development credits, net of the federal tax on state credits												(2.8)	(3.7)	(2.1)
Uncertain tax positions, net of federal benefit												1.9	2.9	2.5
Uncertain tax benefits statute expired, net of federal benefit												(0.4)	(7.1)
Incentive stock option and employee stock purchase plan expense												(0.2)	(3.1)	(1.7)
Foreign rate differential												0.7	0.8	(0.8)
Change in valuation allowance												3.5	(0.2)	0.6
Tax Cut and Jobs Act impact														(32)
Fair value adjustments related to acquisition contingent consideration													0.8	(17)
Non-deductible contingent purchase price and transaction costs												(0.3)
Non-deductible meals and entertainment												1.8	1.3	0.4
Non-deductible officer compensation												1.6	0.6
Asset impairment												12.6
Expired tax attributes												4.2
Non-deductible legal settlement													1.9
Foreign disregarded election													6.4
Changes in revenue recognition/method													(7.3)
Other, net												0.8	0.3	0.5
Total income tax expense	$ (3)	$ (15.9)	$ (3.1)		$ (1.7)	$ (3.4)	$ (3.6)	$ 1	$ 1.6			$ (23.7)	$ (4.4)	$ (13)
[1]	An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 73.1	$ 85.7
Property, plant and equipment	37.2
Accrued vacation	1.5	1.2
AR allowance	1.2	3.3
Stock compensation expense	13.8	16
Research and development credits	27.6	25.4
Lease right-of-use asset	16.3
Uncertain state tax positions	1.6	1.3
Other, net	9.6	9
Total gross deferred tax assets	181.9	141.9
Less valuation allowance	(42.4)	(38.9)
Total deferred tax assets	139.5	103
Deferred tax liabilities:
Intangible assets	150.3	175.4
Lease liability	15.8
Property, plant and equipment		2.5
Deferred revenue		7.7
Total deferred tax liabilities	166.1	185.6
Net deferred tax liability	$ (26.6)	$ (82.6)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended	6 Months Ended		12 Months Ended
	Dec. 31, 2017	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Income Tax Contingency [Line Items]
U.S. federal statutory rate		21.00%	35.00%	21.00%	21.00%	28.10%
Tax Act, incomplete accounting, provisional adjustments	$ (32,600,000)
Earnings per share increase	$ 0.45
Tax Act, incomplete accounting, transition tax for accumulated foreign earnings, provisional income tax expense				$ 0
Amount of valuation allowance increased				3,500,000	$ 1,100,000
Net deferred tax liabilities				166,100,000	185,600,000
Deferred tax assets				181,900,000	141,900,000
Deferred tax liability not recognized, Amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries		$ 0				$ 0
Unrecognized tax benefits		$ 24,900,000		$ 23,500,000	$ 21,700,000	$ 24,900,000	$ 25,200,000
U.S. Federal and State Jurisdictions [Member] | Earliest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2015
U.S. Federal and State Jurisdictions [Member] | Latest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2020
State Tax Authority [Member] | Earliest Tax Year [Member] | State of New Jersey [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2013
State Tax Authority [Member] | Earliest Tax Year [Member] | City of New York [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2014
State Tax Authority [Member] | Latest Tax Year [Member] | State of New Jersey [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2017
State Tax Authority [Member] | Latest Tax Year [Member] | City of New York [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2016
Foreign Tax Authority [Member] | Earliest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2013
Foreign Tax Authority [Member] | Earliest Tax Year [Member] | Federal Ministry of Finance, Germany [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2013
Foreign Tax Authority [Member] | Earliest Tax Year [Member] | Switzerland Federal Tax Administration [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2015
Foreign Tax Authority [Member] | Latest Tax Year [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2020
Foreign Tax Authority [Member] | Latest Tax Year [Member] | Federal Ministry of Finance, Germany [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2015
Foreign Tax Authority [Member] | Latest Tax Year [Member] | Switzerland Federal Tax Administration [Member]
Income Tax Contingency [Line Items]
Tax year being audited in income tax examination				2016
Assurex [Member]
Income Tax Contingency [Line Items]
Net deferred tax liabilities				$ 67,600,000
Deferred tax assets				$ 60,700,000

Income Taxes - Summary of Net O

Income Taxes - Summary of Net Operating Loss and Research Credit Carryforwards (Tax Effected) (Detail) $ in Millions	12 Months Ended
	Jun. 30, 2020USD ($)
Domestic Country [Member] | Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 52.5
Net operating losses subject to sections 382,383	Yes
Domestic Country [Member] | Federal [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2031
Domestic Country [Member] | Federal [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2038
Domestic Country [Member] | Federal [Member] | Research [Member]
Operating Loss Carryforwards [Line Items]
Research credit	$ 11.2
Research credit subject to sections 382,383	Yes
Domestic Country [Member] | Federal [Member] | Research [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2027
Domestic Country [Member] | Federal [Member] | Research [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2040
State and Local Jurisdiction [Member] | UTAH [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 2.7
Net operating losses subject to sections 382,383	No
State and Local Jurisdiction [Member] | UTAH [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2021
State and Local Jurisdiction [Member] | UTAH [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2033
State and Local Jurisdiction [Member] | UTAH [Member] | Research [Member]
Operating Loss Carryforwards [Line Items]
Research credit	$ 11.6
Research credit subject to sections 382,383	No
State and Local Jurisdiction [Member] | UTAH [Member] | Research [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2030
State and Local Jurisdiction [Member] | UTAH [Member] | Research [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2034
State and Local Jurisdiction [Member] | California [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 3.5
Net operating losses subject to sections 382,383	No
State and Local Jurisdiction [Member] | California [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2027
State and Local Jurisdiction [Member] | California [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2040
State and Local Jurisdiction [Member] | California [Member] | Research [Member]
Operating Loss Carryforwards [Line Items]
Research credit	$ 4.7
Research credit subject to sections 382,383	No
State and Local Jurisdiction [Member] | California [Member] | Research [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2027
State and Local Jurisdiction [Member] | California [Member] | Research [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2040
State and Local Jurisdiction [Member] | Other State [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 6.9
Net operating losses subject to sections 382,383	Yes
State and Local Jurisdiction [Member] | Other State [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2027
State and Local Jurisdiction [Member] | Other State [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration in year	2040
State and Local Jurisdiction [Member] | TEXAS [Member] | Research [Member]
Operating Loss Carryforwards [Line Items]
Research credit	$ 0.1
Research credit subject to sections 382,383	No
State and Local Jurisdiction [Member] | TEXAS [Member] | Research [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2039
State and Local Jurisdiction [Member] | TEXAS [Member] | Research [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Research credit, expiration in year	2040
Foreign (various jurisdictions) [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses	$ 7.6
Net operating losses subject to sections 382,383	No
Foreign (various jurisdictions) [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration date ranges	Various
Foreign (various jurisdictions) [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Net operating losses, expiration date ranges	Various

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Beginning and Ending Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Unrecognized tax benefits at the beginning of year	$ 21.7	$ 24.9	$ 25.2
Gross increases - current year tax positions	1.6	2.2	0.6
Gross increases - prior year tax positions	0.7	0.5	2.4
Gross increases - acquisitions		2.3
Gross decreases - prior year tax positions		(0.1)	(3.3)
Gross decreases - settlements		(2.7)
Gross decreases - statute lapse	(0.5)	(5.4)
Unrecognized tax benefits at end of year	23.5	21.7	24.9
Interest and penalties in year-end balance	$ 1.4	$ 0.8	$ 1.5

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Lessee Lease Description [Line Items]
Operating lease weighted average remaining lease term	5 years 3 months 18 days
Operating lease weighted average discount rate percent	3.87%
Rent expense		$ 19.7	$ 15.5
Operating Expense [Member]
Lessee Lease Description [Line Items]
Lease cost	$ 18.4
Variable lease expense	2.6
Short-term lease expense	$ 0.2
Minimum [Member] | Office Spaces, Research and Development Laboratory Facilities, Vehicles and Office Equipment [Member]
Lessee Lease Description [Line Items]
Remaining lease term period	1 year
Maximum [Member] | Office Spaces, Research and Development Laboratory Facilities, Vehicles and Office Equipment [Member]
Lessee Lease Description [Line Items]
Remaining lease term period	7 years

Leases - Maturities of Operatin

Leases - Maturities of Operating Lease Liabilities (Detail) $ in Millions	Jun. 30, 2020USD ($)
Operating Lease Liabilities Payments Due [Abstract]
2021	$ 15.9
2022	14.8
2023	13.6
2024	13.2
2025	10.9
Thereafter	9.6
Total future lease payments	78
Less: amounts representing interest	(7.6)
Present value of future lease payments	70.4
Less: current maturities of operating lease liabilities	13.5
Noncurrent operating lease liabilities	$ 56.9

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Required under Noncancelable Operating Leases (Detail) $ in Millions	Jun. 30, 2019USD ($)
Leases [Abstract]
2020	$ 15.1
2021	14.1
2022	13.1
2023	12.2
2024	11.9
Thereafter	19.1
Total	$ 85.5

Employee Deferred Savings Pla_2

Employee Deferred Savings Plan - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2019
Compensation And Retirement Disclosure [Abstract]
Percent of employee contribution to deferred savings plan	50.00%
Employer's contribution not to exceed percentage of the employees compensation	4.00%

Employee Deferred Savings Pla_3

Employee Deferred Savings Plan - Company Recorded Contributions To Plan (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Compensation And Retirement Disclosure [Abstract]
Deferred savings plan contributions	$ 7.1	$ 8.3	$ 7.2

Segment and Related Informati_3

Segment and Related Information - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2020Segment
Segment Reporting [Abstract]
Number of reportable segment	2

Segment and Related Informati_4

Segment and Related Information - Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) - USD ($) $ in Millions	3 Months Ended									12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Revenues	$ 93.2	$ 164	$ 195.1		$ 186.3	$ 215.4	$ 216.6	$ 216.8	$ 202.3	$ 638.6	$ 851.1	$ 743.7
Depreciation and amortization										72	73	54.4
Segment operating income (loss)	$ (68.3)	$ (133.7)	$ (8.8)		$ (20.9)	$ (5.6)	$ 5.9	$ 6.1	$ 1.2	(231.7)	7.6	121.9
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues										593.5	789.4	690.4
Depreciation and amortization										68.2	67.7	49.2
Segment operating income (loss)										(82.4)	133.3	142.6
Other [Member]
Segment Reporting Information [Line Items]
Revenues										45.1	61.7	53.3
Depreciation and amortization										3.8	5.3	5.2
Segment operating income (loss)										$ (149.3)	$ (125.7)	$ (20.7)
[1]	An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.

Segment and Related Informati_5

Segment and Related Information - Schedule of Total Operating Income for Reportable Segments (Detail) - USD ($) $ in Millions	3 Months Ended									12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting [Abstract]
Total operating income (loss) for reportable segments	$ (68.3)	$ (133.7)	$ (8.8)		$ (20.9)	$ (5.6)	$ 5.9	$ 6.1	$ 1.2	$ (231.7)	$ 7.6	$ 121.9
Interest income	0.5	0.8	0.8		0.9	0.9	0.7	0.9	0.7	3	3.2	1.8
Interest expense	(3.1)	(2.3)	(2.5)		(2.9)	(3.2)	(3.2)	(3.4)	(2.2)	(10.8)	(12)	(3.2)
Other	12.4	4.1	(0.9)		0.6	0.2	(0.1)		1.1	16.2	1.2	(0.4)
Income (loss) before income tax	(58.5)	(131.1)	(11.4)		(22.3)	(7.7)	3.3	3.6	0.8	(223.3)		120.1
Income tax benefit	(3)	(15.9)	(3.1)		(1.7)	(3.4)	(3.6)	1	1.6	(23.7)	(4.4)	(13)
Net income (loss)	(55.5)	(115.2)	(8.3)		(20.6)	(4.3)	6.9	2.6	(0.8)	(199.6)	4.4	133.1
Net loss attributable to non-controlling interest	(0.1)					(0.1)			(0.1)	(0.1)	(0.2)	(0.2)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (55.4)	$ (115.2)	$ (8.3)		$ (20.6)	$ (4.2)	$ 6.9	$ 2.6	$ (0.7)	$ (199.5)	$ 4.6	$ 133.3
[1]	An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.

Segment and Related Informati_6

Segment and Related Information - Schedule Of Comparison Of Balance Sheet Assets By Operating Segment (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	$ 37	$ 57.3
Total assets	1,404.6	1,562.7
Diagnostics [Member]
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	23.9	25.7
Total assets	1,002.8	1,215.6
Other [Member]
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	13.1	31.6
Total assets	147	155.3
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total assets	$ 1,149.8	$ 1,370.9

Segment and Related Informati_7

Segment and Related Information - Summary of Assets by Geographical Region (Detail) - USD ($) $ in Millions	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	$ 37	$ 57.3
Total assets	1,404.6	1,562.7
United States [Member]
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	35.4	36
Total assets	1,097.2	1,265.8
Rest of World [Member]
Segment Reporting Information [Line Items]
Net equipment, leasehold improvements and property	1.6	21.3
Total assets	52.6	105.1
Reportable Geographical Components [Member]
Segment Reporting Information [Line Items]
Total assets	$ 1,149.8	$ 1,370.9

Segment and Related Informati_8

Segment and Related Information - Reconciliation of Assets by Operating Segment and Geographic Region to Total Assets (Detail) - USD ($) $ in Millions		Jun. 30, 2020	Jun. 30, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Assets		$ 1,404.6	$ 1,562.7
Operating segments and geographic region [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets		1,149.8	1,370.9
Cash, cash equivalents, and marketable investment securities [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	[1]	$ 254.8	$ 191.8
[1]	The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments.

Sale of Subsidiary - Additional

Sale of Subsidiary - Additional Information (Detail) - USD ($) $ in Millions	Feb. 28, 2020	Jun. 30, 2020
Disposal of Subsidiary [Line Items]
Pre-tax net gain on sale		$ 1
Clinic Asset Group [Member]
Disposal of Subsidiary [Line Items]
Pre-tax net gain on sale	$ 1
Pre-tax gain by settlement	1.2
Offset by a loss, due to the difference between the purchase price and net assets	$ 0.2

Business Acquisitions - Additio

Business Acquisitions - Additional Information (Detail) $ / shares in Units, $ in Millions	Jul. 31, 2018USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)
Business Acquisition [Line Items]
Goodwill, working capital adjustment reduction		$ 4.4
Counsyl Inc [Member]
Business Acquisition [Line Items]
Business acquisition consideration	$ 405.9
Goodwill, working capital adjustment reduction			$ (1.1)
Intangible assets reduction due to assumptions related to contributory asset charges		2.9
Decrease in deferred tax liabilities		1.9	1.9
Fair value equipment reduction		0.7	0.7
Increase in goodwill		4.4
Acquired intangible assets	290
Acquisition costs			$ 6.8
Revenue contributed by acquired entity		104.9
Operating expenses related to acquired entity		67.6
Counsyl Inc [Member] | Developed Screening Processes [Member]
Business Acquisition [Line Items]
Acquired intangible assets	$ 290
Intangible assets estimated useful lives	12 years
Counsyl Inc [Member] | Developed Screening Processes [Member] | Measurement Input, Discount Rate [Member]
Business Acquisition [Line Items]
Estimated net cash flows, discount rate	12.5
Counsyl Inc [Member] | Agreement and Plan of Merger [Member]
Business Acquisition [Line Items]
Effective date of business acquisition	Jul. 31, 2018
Business acquisition consideration	$ 405.9
Cash payment on business acquisition	278.5
Amount of cash consideration deposited in escrow account	$ 5
Goodwill, working capital adjustment reduction		$ 1.1
Counsyl Inc [Member] | Agreement and Plan of Merger [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Business acquisition, shares issued | shares	2,994,251
Business acquisition, shares issued, value	$ 127.4
Business acquisition, per share market closing price | $ / shares	$ 42.53

Business Acquisitions - Allocat

Business Acquisitions - Allocation of Consideration Transferred (Detail) - USD ($) $ in Millions	Jul. 31, 2018	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2018	Jun. 30, 2018
Business Acquisition [Line Items]
Goodwill		$ 327.6	$ 417.2		$ 318.6
Counsyl Inc [Member]
Business Acquisition [Line Items]
Current assets	$ 42.5
Intangible assets	290
Equipment	18.2
Other assets	0.1
Goodwill	99.3	$ 99.3		$ 94.9
Current liabilities	(19.6)
Long term liabilities	(0.1)
Deferred tax liability	(9.2)
Total fair value purchase price	421.2
Less: Cash acquired	(15.3)
Total consideration transferred	$ 405.9

Business Acquisitions - Summary

Business Acquisitions - Summary of Changes to Goodwill Balance (Detail) - USD ($) $ in Millions	12 Months Ended	21 Months Ended
	Jun. 30, 2019	Jun. 30, 2020
Goodwill [Line Items]
Beginning balance	$ 318.6
Working capital adjustment	4.4
Ending balance	417.2	$ 327.6
Counsyl Inc [Member]
Goodwill [Line Items]
Beginning balance		94.9
Fair value adjustment to equipment	0.7	0.7
Intangible adjustment		2.9
Working capital adjustment		(1.1)
Change in deferred tax liability	$ 1.9	1.9
Ending balance		$ 99.3

Business Acquisitions - Pro For

Business Acquisitions - Pro Forma Results of Acquisitions (Detail) - Counsyl Inc [Member] - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Business Acquisition [Line Items]
Revenue	$ 861.3	$ 881.8
Income from operations	17.9	74.3
Net income	$ 13.8	$ 73
Net income per share, basic	$ 0.19	$ 1.01
Net income per share, diluted	$ 0.18	$ 0.98

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jul. 01, 2019
Cash paid for income taxes	$ 1	$ 6.5	$ 11.7
Cash paid for interest	9.5	11.6	3
Non-cash investing and financing activities:
Fair value adjustment on marketable investment securities recorded to stockholders' equity	0.7	$ 1.2	$ (0.4)
Establishment of operation lease right-of-use assets and lease liabilities
Operating lease right-of-use assets	66
Operating lease liabilities	(70.4)
Accrued liabilities and other long-term liabilities	4.3
ASU 2016-02 [Member]
Establishment of operation lease right-of-use assets and lease liabilities
Operating lease right-of-use assets	74.5			$ 74.5
Operating lease liabilities	$ (78.8)			$ (78.8)

Supplementary Quarterly Finan_3

Supplementary Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended									12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Total revenue	$ 93.2	$ 164	$ 195.1		$ 186.3	$ 215.4	$ 216.6	$ 216.8	$ 202.3	$ 638.6	$ 851.1	$ 743.7
Costs and expenses:
Research and development expense	17.4	19.7	18.8		21.3	20.9	21.5	22.4	21.1	77.2	85.9	70.8
Change in the fair value of contingent consideration		(3.4)	(0.1)		0.7	(0.3)		1	0.4	(2.8)	1.1	(61.2)
Selling, general, and administrative expense	107.4	132.9	134.3		135.5	149.8	140.6	135.2	129.9	510.1	555.5	435
Goodwill and intangible asset impairment charges		98.4	1.3							99.7
Total costs and expenses	161.5	297.7	203.9		207.2	221	210.7	210.7	201.1	870.3	843.5	621.8
Operating income (loss)	(68.3)	(133.7)	(8.8)		(20.9)	(5.6)	5.9	6.1	1.2	(231.7)	7.6	121.9
Other income (expense):
Interest income	0.5	0.8	0.8		0.9	0.9	0.7	0.9	0.7	3	3.2	1.8
Interest expense	(3.1)	(2.3)	(2.5)		(2.9)	(3.2)	(3.2)	(3.4)	(2.2)	(10.8)	(12)	(3.2)
Other	12.4	4.1	(0.9)		0.6	0.2	(0.1)		1.1	16.2	1.2	(0.4)
Total other income (expense):	9.8	2.6	(2.6)		(1.4)	(2.1)	(2.6)	(2.5)	(0.4)	8.4	(7.6)	(1.8)
Income (loss) before income tax	(58.5)	(131.1)	(11.4)		(22.3)	(7.7)	3.3	3.6	0.8	(223.3)		120.1
Income tax provision (benefit)	(3)	(15.9)	(3.1)		(1.7)	(3.4)	(3.6)	1	1.6	(23.7)	(4.4)	(13)
Net income (loss)	(55.5)	(115.2)	(8.3)		(20.6)	(4.3)	6.9	2.6	(0.8)	(199.6)	4.4	133.1
Net loss attributable to non-controlling interest	(0.1)					(0.1)			(0.1)	(0.1)	(0.2)	(0.2)
Net income (loss) attributable to Myriad Genetics, Inc. stockholders	$ (55.4)	$ (115.2)	$ (8.3)		$ (20.6)	$ (4.2)	$ 6.9	$ 2.6	$ (0.7)	$ (199.5)	$ 4.6	$ 133.3
Earnings (loss) per share:
Basic	$ (0.74)	$ (1.55)	$ (0.11)		$ (0.28)	$ (0.06)	$ 0.09	$ 0.04	$ (0.01)	$ (2.69)	$ 0.06	$ 1.92
Diluted	$ (0.74)	$ (1.55)	$ (0.11)		$ (0.28)	$ (0.06)	$ 0.09	$ 0.03	$ (0.01)	$ (2.69)	$ 0.06	$ 1.85
Weighted average shares outstanding:
Basic	74.6	74.5	74.4		73.7	73.4	73.3	74.2	73	74,300,000	73,500,000	69,400,000
Diluted	74.6	74.5	74.4		73.7	74.8	74.9	76.5	73	74,300,000	76,000,000	72,000,000
Molecular Diagnostic Testing [Member]
Total revenue	$ 83.3	$ 150.5	$ 181.1		$ 172	$ 196.9	$ 200.5	$ 203	$ 189	$ 586.9	$ 789.4	$ 690.4
Costs and expenses:
Total costs and expenses	32.2	43.1	41		41.2	41.6	40.3	44	42.3	157.5	168.2	148.7
Pharmaceutical and Clinical Services [Member]
Total revenue	9.9	13.5	14		14.3	18.5	16.1	13.8	13.3	51.7	61.7	53.3
Costs and expenses:
Total costs and expenses	$ 4.5	$ 7	$ 8.6		$ 8.5	$ 9	$ 8.3	$ 8.1	$ 7.4	$ 28.6	$ 32.8	$ 28.5
[1]	An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.

Supplementary Quarterly Finan_4

Supplementary Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2020
Goodwill impairment charge		$ 82
Immaterial Prior Period [Member] | Selling, General, and Administrative Expenses [Member]
Goodwill impairment charge	$ 1.3